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A B S T R A C T
Background
Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after
treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes
are beneficial, it is not known if the same treatments are effective for childhood cancer patients and survivors with anthracycline-
induced cardiotoxicity. This review is an update of a previously published Cochrane review.
Objectives
To compare the effect of medical interventions on anthracycline-induced cardiotoxicity in childhood cancer patients or survivors with
the effect of placebo, other medical interventions, or no treatment.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2015, Issue 8), MEDLINE/
PubMed (1949 to September 2015), and EMBASE/Ovid (1980 to September 2015) for potentially relevant articles. In addition, we
searched reference lists of relevant articles, conference proceedings of the International Society for Paediatric Oncology (SIOP), the
American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the International Conference on Long-
Term Complications of Treatment of Children & Adolescents for Cancer, and the European Symposium on Late Complications from
Childhood Cancer (from 2005 to 2015), and ongoing trial databases (the ISRCTN Register, the National Institutes of Health (NIH)
Register, and the trials register of the World Health Organization (WHO); all searched in September 2015).
Selection criteria
Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing the effectiveness of medical interventions to treat
anthracycline-induced cardiotoxicity with either placebo, other medical interventions, or no treatment.
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Data collection and analysis
Two review authors independently performed the study selection. One review author performed the data extraction and ’Risk of bias’
assessments, which another review author checked. We performed analyses according to the guidelines in the Cochrane Handbook for
Systematic Reviews of Interventions.
Main results
In the original versionof the reviewwe identified twoRCTs; in this updatewe identifiedno additional studies.One trial (135 participants)
compared enalapril with placebo in childhood cancer survivorswith asymptomatic anthracycline-induced cardiac dysfunction.The other
trial (68 participants) compared a two-week treatment of phosphocreatine with a control treatment (vitamin C, adenosine triphosphate,
vitamin E, oral coenzyme Q10) in leukaemia patients with anthracycline-induced cardiotoxicity. Both studies had methodological
limitations.
The RCT on enalapril showed no statistically significant differences in overall survival, mortality due to heart failure, development
of clinical heart failure, and quality of life between treatment and control groups. A post-hoc analysis showed a decrease (that is
improvement) in one measure of cardiac function (left ventricular end-systolic wall stress (LVESWS): -8.62% change) compared with
placebo (+1.66% change) in the first year of treatment (P = 0.036), but not afterwards. Participants treated with enalapril had a higher
risk of dizziness or hypotension (risk ratio 7.17, 95% confidence interval 1.71 to 30.17) and fatigue (Fisher’s exact test, P = 0.013).
TheRCTonphosphocreatine found no differences in overall survival, mortality due to heart failure, echocardiographic cardiac function,
and adverse events between treatment and control groups.
Authors’ conclusions
Only one trial evaluated the effect of enalapril in childhood cancer survivors with asymptomatic cardiac dysfunction. Although there
is some evidence that enalapril temporarily improves one parameter of cardiac function (LVESWS), it is unclear whether it improves
clinical outcomes. Enalapril was associated with a higher risk of dizziness or hypotension and fatigue. Clinicians should weigh the
possible benefits with the known side effects of enalapril in childhood cancer survivors with asymptomatic anthracycline-induced
cardiotoxicity.
Only one trial evaluated the effect of phosphocreatine in childhood cancer patients with anthracycline-induced cardiotoxicity. Limited
data with a high risk of bias showed no significant difference between phosphocreatine and control treatments on echocardiographic
function and clinical outcomes.
We did not identify any RCTs or CCTs studying other medical interventions for symptomatic or asymptomatic cardiotoxicity in
childhood cancer patients or survivors.
High-quality studies should be performed.
P L A I N L A N G U A G E S U M M A R Y
Treatment for cardiac problems caused by anthracycline chemotherapy for childhood cancer
Anthracyclines are anticancer drugs used in the treatment of different types of childhood cancer. An important adverse effect of
anthracyclines is damage to the heart, which can lead to asymptomatic (without complaints) or symptomatic (with complaints) cardiac
problems during and after cancer treatment. While there are several drugs available to treat other types of cardiac problems in adults,
it is not known if these drugs are beneficial in treating cardiac problems caused by anthracyclines in childhood cancer patients and
survivors. A physician confronted with a childhood cancer patient or survivor with anthracycline-induced cardiac problems should be
able to make an informed decision on how to treat this patient based on high-quality evidence about the beneficial and adverse effects
of the treatment options. We searched for and summarised studies that evaluated drugs for treating anthracycline-induced cardiac
problems in childhood cancer patients and survivors.
We identified two randomised studies evaluating twodifferent drugs in twodifferent types of patients.One of these drugs, an angiotensin-
converting enzyme (ACE) inhibitor (enalapril), had a short-termbeneficial effect on heart function in survivors of childhood cancer with
asymptomatic cardiac problems caused by anthracyclines compared with placebo. However, the drug had no significant beneficial effect
on other important outcomes andwas associatedwith side effects such as dizziness and fatigue. This studywas of reasonable/good quality.
The other study was of low quality and found no effect of a short treatment with phosphocreatine in childhood leukaemia patients with
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symptomatic or asymptomatic cardiac problems compared with a control treatment with vitamin C, adenosine triphosphate, vitamin
E, and oral coenzyme Q10.
We could make no definitive conclusions about treatment options for anthracycline-induced cardiac problems in childhood cancer
patients and survivors. High-quality studies are needed to determine if there are drugs that improve heart function in these patients.
B A C K G R O U N D
Description of the condition
Anthracyclines are frequently used chemotherapeutics for child-
hood cancer that can cause serious cardiac dysfunction (Lefrak
1973; Van Dalen 2014; Von Hoff 1977). This so-called anthra-
cycline-induced cardiotoxicity can develop during, or many years
after, treatment and may present clinically, with symptoms of
heart failure (Mulrooney 2009; Van der Pal 2012), or subclini-
cally, with abnormalities found only in diagnostic tests (Ganame
2007; Lipshultz 1991; Van Dalen 2006a). It is estimated that al-
most 10% of childhood cancer patients treated with anthracycline
doses of 300 mg/m² or more will eventually develop symptomatic
cardiotoxicity, a condition that is associated with high morbid-
ity and mortality (Steinherz 1995; Van Dalen 2006a). Asymp-
tomatic signs of cardiotoxicity are found in up to 57% of survivors
of childhood cancer and are often progressive over time, but the
long-term prognosis of these abnormalities is not known (Kremer
2002; Lipshultz 2005a; Sorensen 2003). In the general adult pop-
ulation, individuals with asymptomatic cardiac dysfunction are at
increased risk of developing symptomatic heart failure and death
(Wang 2003). These findings raise the concern that children and
young adults with asymptomatic cardiac dysfunction caused by
anthracyclines are also at risk of progression to symptomatic heart
failure in the long term.
Description of the intervention
Several cardiovascular drugs have been studied in people with car-
diac dysfunction due to other causes. Studies in adults with symp-
tomatic as well as asymptomatic heart failure due to causes other
than anthracyclines have shown that treatment of an average du-
ration of three years with angiotensin-converting enzyme (ACE)
inhibitors reduces long-term morbidity and mortality, regardless
of the aetiology of heart failure (Abdulla 2006; Garg 1995; Jong
2003; SOLVD 1991; SOLVD 1992). The Studies of Left Ventric-
ular Dysfunction (SOLVD) also showed an improvement in qual-
ity of life in symptomatic participants and no negative effect in
quality of life in asymptomatic participants (Rogers 1994; SOLVD
1991; SOLVD1992). A cost-effectiveness study was performed in
symptomatic SOLVD patients and showed survival benefit as well
as cost savings (Glick 1995). Treatment with beta-blocking agents
in addition to an ACE inhibitors improves the mortality outcome
in people with symptomatic cardiac failure (CIBIS-II 1999; Foody
2002; Packer 1996a; Packer 1996b; Waagstein 1993), and im-
proves cardiac function in people with asymptomatic heart failure
(Colucci 2007; Exner 1999). Other medical interventions may
also potentially improve the prognosis of people with symptomatic
or asymptomatic heart failure, such as angiotensin receptor block-
ers (Granger 2003 and Maggioni 2002), or combinations of heart
failure medications, such as angiotensin receptor blockers, ACE
inhibitors, and beta-blockers (Cohn 2001; McMurray 2003).
Why it is important to do this review
Many collaborative groups have advocated screening for cardiac
dysfunction in childhood cancer patients and survivors (Armenian
2014; Armenian 2015; COG 2006; Sieswerda 2012; SIGN 2013;
Skinner 2005; Steinherz 1992). However, for appropriate screen-
ing for a disease, an effective treatment should be available (Wilson
1968). In addition, physicians who are confronted with childhood
cancer patients and survivors with cardiac dysfunction should be
able to make a well-informed decision regarding the risks and
benefits of treatment options. The optimal treatment for people
with anthracycline-induced cardiotoxicity, and how to decrease
morbidity and mortality, are currently unclear (Lipshultz 2002;
Silber 2004; Van Dalen 2003). Although medical interventions
in populations with symptomatic and asymptomatic heart failure
due to causes other than anthracyclines are beneficial, we cannot
assume that the efficacy of this treatment is similar in childhood
cancer patients and survivors (Kay 2001; Shaddy 2007). The dif-
ferent aetiology of the cardiac dysfunction, as well as the different
age distribution, make it necessary to study the benefits and risks
of treatment of symptomatic and asymptomatic anthracycline-in-
duced cardiotoxicity in this specific population. Treatment of peo-
ple with anthracycline-induced cardiotoxicity should ideally de-
crease morbidity and mortality, improve cardiac function, reverse
disease progression, and improve quality of life.
This is an update of the first systematic review, Sieswerda 2011,
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evaluating the current available evidence on medical interventions
in both symptomatic and asymptomatic anthracycline-induced
cardiotoxicity during and after treatment for childhood cancer.
O B J E C T I V E S
To compare the effect of medical interventions on anthracycline-
induced cardiotoxicity in childhood cancer patients or survivors
with the effect of placebo, othermedical interventions, or no treat-
ment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical tri-
als (CCTs) (as defined by the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2008)), including non-inferior-
ity and cross-over trials, comparing a medical intervention for
treating anthracycline-induced cardiotoxicity with either placebo,
other medical intervention(s), or no treatment.
Types of participants
Patients and survivors (previously) diagnosed with any type of
childhood cancer (defined as a diagnosis of cancer at age 18 years
or younger) and with symptomatic or asymptomatic anthracy-
cline-induced cardiotoxicity. RCTs or CCTs including both chil-
dren and adults were only eligible for inclusion in this review if
the majority of participants were 18 years or younger at cancer
diagnosis. Anthracycline-induced cardiotoxicity, as defined by the
authors of the original study, could be diagnosed both during and
after anthracycline treatment for childhood cancer. Due to the low
number of patients expected, we did not exclude patients who also
had been treated with mediastinal radiotherapy.
Types of interventions
Medical (that is drug) interventions given with the intention
to change the course of anthracycline-induced symptomatic or
asymptomatic cardiotoxicity. We excluded surgical interventions
such as heart transplantation.
Types of outcome measures
Primary outcomes
1. Overall survival.
2. Mortality due to heart failure.
3. Development of clinical heart failure as defined by authors.
4. Occurrence of adverse events and tolerability as defined by
authors.
Secondary outcomes
1. Change in cardiac function measured by different
diagnostic tests as defined by authors.
2. (Duration of ) hospitalisation for heart failure.
3. Change in NYHA (New York Heart Association) stage of
heart failure (NYHA 1994).
4. Change in quality of life as defined by authors.
5. Costs as defined by authors.
Outcomes may have been assessed at any time during follow-up.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (the Cochrane Library, 2015, Issue 8), MED-
LINE/PubMed (1949 to 25 September 2015), and EMBASE/
Ovid (1980 to 25 September 2015) for potentially relevant arti-
cles.
The search strategies for CENTRAL, MEDLINE/PubMed, and
EMBASE/Ovid are shown in Appendix 1, Appendix 2, and
Appendix 3.We used the highly sensitive search strategy for identi-
fying reports of RCTs and CCTs (sensitivity-maximizing version)
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2008).
We scanned the ISRCTNRegister (www.isrctn.com), theNational
Institutes of Health (NIH) Register (www.clinicaltrials.gov), and
the trials register of the World Health Organization (WHO) (
apps.who.int/trialsearch/) on 29 September 2015. The search key-
words are shown in Appendix 4.
There were no language restrictions.
Searching other resources
We located information about trials not registered in CENTRAL,
MEDLINE/PubMed, or EMBASE/Ovid, either published or un-
published, by searching the reference lists of relevant articles and
review articles. In addition, we handsearched conference proceed-
ings of the International Society for Paediatric Oncology (SIOP),
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the American Society of Clinical Oncology (ASCO), the Ameri-
can Society of Hematology (ASH), the International Conference
on Long-Term Complications of Treatment of Children & Ado-
lescents for Cancer, and the European Symposium on Late Com-
plications from Childhood Cancer from 2005 up to and includ-
ing 2015. Again, there were no language restrictions. The search
keywords are shown in Appendix 5.
Data collection and analysis
Selection of studies
After employing the search strategy described above, two review
authors independently identified studies meeting the criteria for
this review. We obtained in full any study which seemed to meet
the inclusion criteria on the grounds of the title, abstract, or both
for closer inspection. The review authors included or excluded
studies for this review based on full-text assessment. Two studies
selected for full-text evaluation were not in a language the authors
were familiar with; for these, we contacted Cochrane collaborators
fromRussia andChina, who individually determined if the studies
were eligible. We recorded the reasons for exclusion of any study
considered for the review. Discrepancies in the selection process
were resolved between authors by consensus, or in case of doubt,
by consulting a third-party arbitrator.
One review author performed the search of reference lists of rel-
evant articles and review articles, as well as the search within the
conference proceedings.
We have constructed a flow diagram.
Data extraction and management
One review author performed data extraction using standardised
forms, which a second review author checked. For the study pub-
lished in Chinese, this was done by a review author from China
based on full text and checked by another review author based
on the abstract only. We abstracted information on the following
items:
1. study design;
2. ’Risk of bias’ items;
3. number of study participants;
4. participants, including:
i) age at diagnosis;
ii) age at study entry;
iii) sex;
iv) time since diagnosis;
v) study performed during cancer treatment or in
survivors;
vi) in case of survivors, time since end of cancer treatment;
vii) prior anthracycline treatment, including:
a) type of anthracycline;
b) cumulative anthracycline dose;
viii) other previous treatment, including:
a) chemotherapy;
b) cardioprotective interventions;
c) radiotherapy on heart region;
ix) comorbidities, including:
a) cardiovascular disease (specification disease, cause
and duration of disease before start of intervention);
b) other (specification disease, cause and duration of
disease before start of intervention);
x) other treatment, including:
a) other cardiovascular medication (agent, dose,
frequency, mode of administration, and duration);
b) other medication (agent, dose, frequency, mode
of administration, and duration);
c) cardiovascular surgery (location and procedure);
5. interventions, including:
i) type of medical intervention (substance name, brand
name);
ii) dose and frequency of medical intervention;
iii) mode of administration (oral, intravenous, etc.);
iv) duration of medical intervention;
v) duration between diagnosis of anthracycline-induced
cardiotoxicity and start of medical intervention;
6. outcome measures, including:
i) outcome definition;
ii) timing of outcome measurement;
7. length of follow-up.
In cases of disagreement, we re-examined the abstracts and articles
and discussed the topic until consensus was achieved. No third-
party arbitration was needed.
Assessment of risk of bias in included studies
One review author assessed the risk of bias using a standardised
form, which was checked by another review author. The study
published in Chinese was assessed by a review author from China
based on full text and checked by another review author based
on the (English) abstract only. We evaluated the studies according
to the following criteria: generation of allocation sequence, con-
cealment of treatment allocation, blinding of the study partici-
pants, blinding of personnel, blinding of outcome assessors, com-
pleteness of follow-up, intention-to-treat (ITT) analysis, selective
outcome reporting, and other sources of bias. We determined the
items blinding of outcome assessors, completeness of follow-up,
and ITT analysis for all reported study outcomes. Only for overall
survival, we regarded blinding of the outcome assessor not rele-
vant. For all ’Risk of bias’ items, we used definitions based on the
module of Cochrane Childhood Cancer at the time our protocol
was published (Module CCG), and on the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008) (see additional
Table 1).We resolved discrepancies between authors by consensus.
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In case of doubt, we consulted a third-party arbitrator.
Measures of treatment effect
We related dichotomous outcomes to risk using the risk ratio (RR)
and presented all results with the corresponding 95% confidence
interval (CI). When only one study was available and there were
no events in one of the treatment groups, it was not appropriate to
calculate the RR, its 95% CI, and the corresponding P value. For
these outcomes, we calculated the Fisher’s exact P value instead,
using PASW Statistics (SPSS) forWindows version 18 (SPSS Inc.,
Chicago, IL, USA). We planned to analyse continuous outcomes
using the mean difference (MD). However, this was not possible
since no standard deviation (SD) of change in the continuous
outcomeswas provided by the included studies. For the assessment
of survival, we planned to use Parmar’s method if hazard ratios
had not been explicitly presented in the study (Parmar 1998).
However, this was not applicable, since we could not pool the
included studies.
Dealing with missing data
When information relevant to study selection was missing, we
attempted to contact the authors in order to obtain the missing
data.
We extracted data by allocated intervention, irrespective of com-
pliance with the allocated intervention, in order to allow an ITT
analysis. If this was not possible, we stated this and performed an
as-treated analysis.
Assessment of heterogeneity
Assessing heterogeneity was not applicable, since we did not pool
the included studies.
Assessment of reporting biases
Wewere not able to construct a funnel plot to evaluate the existence
of publication bias graphically (Higgins 2008), since we included
only two trials in this review andpooling of resultswas not possible.
As a rule of thumb, tests for funnel plot asymmetry should be
used only when there are at least 10 studies included in the meta-
analysis. When there are fewer studies, the power of the tests is too
low to distinguish chance from real asymmetry (Higgins 2008).
Data synthesis
We entered the data into RevMan 5.3 (RevMan 2014), and anal-
ysed according to the guidelines of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008). We used a ran-
dom-effectsmodel for the estimation of treatment effects through-
out the review.
We included outcome measures in this systematic review only if
it was the intention of the study authors to perform the necessary
assessments in all randomised participants (that is not optional
or only performed in some centres). When less than 50% of the
participants in a study had an acceptable follow-up for a particular
outcome measure, due to the associated high risk of attrition bias
we did not report the results of this outcome measure.
We did not perform a pooled analysis since the included trials
were not comparable with regard to important study characteris-
tics, that is age, sex, cardiac dysfunction, treatment used, outcome
definitions, and length of follow-up.We therefore summarised the
results descriptively.
We planned to analyse data separately for clinical heart failure
alone versus no clinical heart failure and for clinical and subclinical
cardiotoxicity combined versus normal heart function. However,
this was not applicable, since pooling was not possible and the
study that included both participants with clinical and subclinical
heart failure did not provide enough information to allow for such
an analysis.
Subgroup analysis and investigation of heterogeneity
We hypothesised that treatment with mediastinal radiotherapy
could cause other cardiac pathology, such as heart valve problems,
and that it is therefore possible that treatment effects would differ
between patients treated with and without mediastinal radiother-
apy. However, we were not able to investigate this type of hetero-
geneity by performing a subgroup analysis with regard to previous
mediastinal radiotherapy because pooling was not possible and be-
cause the individual studies did not provide outcomes separately
for participants treated with and without previous radiotherapy.
Sensitivity analysis
Since we could not pool results, performing a sensitivity analysis
using the ’Risk of bias’ criteria was not applicable.
R E S U L T S
Description of studies
Results of the search
Our original searches in the electronic databases CENTRAL,
MEDLINE/PubMed, and EMBASE/Ovid identified 1429 titles
with or without an abstract. In the update search of these electronic
databases, we identified an additional 480 titles (442 records af-
ter removal of duplicates) (Figure 1), of which we selected eight
references reporting on five studies for full-text assessment. No
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additional reference in the update search was selected for full-text
assessment. We did not include the remaining 1863 papers be-
cause they were not RCTs or CCTs, were laboratory studies, ani-
mal studies, did not include children with cancer or survivors of
childhood cancer, or were preventive intervention studies of peo-
ple without signs of cardiotoxicity. While examining the reference
lists of relevant papers, we found an additional five papers, report-
ing on two studies (of which one was already identified in the
electronic database search), which we also assessed in full text. We
identified no new studies in the current update search. In total,
we assessed the full text of 13 papers reporting on seven studies.
Figure 1. Study flow diagram.
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Based on full-text assessment, we finally included in this review
seven papers reporting on two studies. We excluded six papers
reporting on five studies. We have listed reasons for exclusion in
the Characteristics of excluded studies table.
By scanning the conference proceedings of relevant conferences,
we identified two papers that have not yet been published in full
text and are awaiting further assessment (see the Characteristics
of studies awaiting classification table). By scanning the ongoing
trials databases, we identified one additional ongoing trial (see the
Characteristics of ongoing studies table). We identified no addi-
tional studies in the current update search of conference proceed-
ings and trials databases.
Included studies
We included two RCTs with a total of 203 participants in the
review (Chen 2008; Silber 2004); we identified no new studies in
the current update. Six papers provided information on one trial
(see all references under Silber 2004). We extracted information
about the study from all six papers.
In one trial, 69 participants received enalapril and 66 participants
received placebo (Silber 2004). Participants were childhood can-
cer survivors with asymptomatic decline of cardiac function at
some time during follow-up after anthracycline exposure. Follow-
up time was a median of 2.80 (range 2 weeks to 6.1 years).
In the other trial, 35 participants received phosphocreatine and 33
participants received a control treatment with vitamin C, adeno-
sine triphosphate (ATP), vitamin E, and oral coenzyme Q10
(Chen 2008). Participants were children with acute leukaemia
and anthracycline-induced cardiotoxicity, part of whichwas symp-
tomatic. The duration of treatment was 14 days, and assessment
of cardiac function was performed one day after the end of treat-
ment; it is unclear if there was longer follow-up, for example for
the clinical outcomes.
For more information see the Characteristics of included studies
table.
Excluded studies
The number of excluded papers based on full-text evaluation was
six in total, reporting on five studies. A summary of the excluded
studies can be found in the Characteristics of excluded studies
table.
Risk of bias in included studies
We have summarised the evaluation of the risk of bias in the in-
cluded studies below. An additional overview of evaluation in each
domain per included study is provided in the Characteristics of
included studies table (’Risk of bias’ section) and summarised in
Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
In the enalapril study, allocation to treatment or control group was
at random. For the allocation sequence, random permuted blocks
with equal allocationwere usedwithin each stratumof prespecified
variables (Silber 2004). Allocation was described as concealed, but
the method of allocation concealment was not stated and was
therefore unclear.
In the phosphocreatine study, allocation to treatment or control
group was also at random, but the method used to generate the
allocation sequence was not described (Chen 2008). It was not
stated if there was allocation concealment.
Blinding
The enalapril trial was reported to be a double-blind study (Silber
2004). Although how the blinding was done was not clearly de-
scribed, one of the additional papers concerning the trial stated
that participants truly did not know which of the two treatments
they had received (Silber 2004), indicating that blinding of par-
ticipants was effective. It was also clearly stated that investigators
were blinded to the intervention. However, it was not specified if
the blinding of investigators concerned personnel as well as out-
come assessors, if it was applicable to all studied outcomes, or if
it was effective. Based on the effectiveness of blinding of partici-
pants and the statement that participants and investigators were
blinded, we judged that this probably was the case. We consulted
a third party regarding this judgement, who agreed with it.
In the phosphocreatine trial, blinding was not described and based
on the different types of route of administration per treatment
and control group, we judged that blinding of participants and
personnel was very unlikely (Chen 2008). It was not stated if the
investigators or outcome assessors were blinded, and we therefore
we judged it to be unclear.
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Incomplete outcome data
In the enalapril trial, follow-up was complete for overall survival,
mortality due to heart failure, and development of clinical heart
failure (Silber 2004). Follow-upwas complete for change in cardiac
function for the study outcomes maximal cardiac index (MCI)
and left ventricular end-systolic wall stress (LVESWS), which were
both measured in at least one post-baseline measurement in more
than 80% of the participants. However, it should be noted that it
was unclear if follow-up was complete for these parameters at the
end of follow-up. For other measures of cardiac function (short-
ening fraction (SF) and stress-velocity index (SVI)) and the other
outcomes that were reported (occurrence of adverse events and
change in quality of life), it was unclear if the follow-up was com-
plete. One of the additional papers concerning this trial stated
that a considerable fraction of the study participants ended par-
ticipation, but did not report exact numbers and timing of study
dropouts (Silber 2004). It was clearly stated that intention-to-
treat (ITT) analysis was performed for the trial’s primary and sec-
ondary outcomes. An extra per-protocol analysis was performed
on LVESWS. For the other measures of cardiac function (SF and
SVI) it was unclear if an ITT analysis was performed. For overall
survival, mortality due to heart failure, development of clinical
heart failure, change in quality of life, and occurrence of adverse
events, ITT analysis was possible, since the treatment allocation
was abstractable for the reported outcomes.
In the phosphocreatine trial, complete assessment was done for
overall survival, mortality due to heart failure, and occurrence
of adverse events (Chen 2008). For change in cardiac function,
two parameters (echocardiography and hyper-sensitivity C-reac-
tive protein (hsCRP)) were reported in all participants, while the
other parameters of change in cardiac function outcomes (elec-
trocardiogram (ECG), creatine kinase (CK), creatine kinase MB
(CK-MB), lactate dehydrogenase (LDH1), and alpha hydroxybu-
tyrate dehydrogenase (alphaHBDH)) were only assessed in some
participants and therefore not reported in this review. For overall
survival, mortality due to heart failure, two parameters of change
in cardiac function (echocardiography and hsCRP), and the oc-
currence of adverse events, ITT analysis was possible, since the
treatment allocation was abstractable for all reported outcomes.
Selective reporting
There was no sign of selective reporting in the enalapril trial (Silber
2004). A protocol was published that presented the outcomes that
were planned to be studied as well as the planned data analyses
(Silber 2004). All outcomes were reported and the analyses done
in the final report (Silber 2004). The authors clearly explained that
they performed some additional analyses based on exploration of
the data.
In the phosphocreatine trial, there was no published protocol, and
we therefore cannot exclude selective reporting bias in the study
(Chen 2008).
Other potential sources of bias
In the enalapril trial, we were not aware of other potential issues
that could put the study at a high risk of bias (Silber 2004).
In the phosphocreatine study, we had concerns about the com-
parability of the study participants, especially with regard to po-
tential confounders such as gender, age, cumulative anthracycline
dose, type of anthracycline, other cardiotoxic treatment, number
of symptomatic participants, and the provision of other treatments
during the study (Chen 2008).
Effects of interventions
Both trials did not allow data extraction for all endpoints. See
the Characteristics of included studies table for a more detailed
description of the extractable endpoints of each study.
Overall survival and mortality due to heart failure
We could extract data on overall survival and mortality due to
heart failure from both studies.
In the enalapril trial, there were no deaths in both the intervention
and the control group during the study (Silber 2004). However,
one participant from the placebo group (1.5%) died eight months
after the end of the study, as a result of congestive heart failure. As it
was unclear if both the intervention group and placebo group had
been followed beyond the end of the study, we did not calculate
a risk ratio (RR) of death due to heart failure including this late
death.
In the phosphocreatine trial, there were no deaths in both the
intervention and the control group during the study (Chen 2008).
Development of clinical heart failure (as defined by
authors)
The enalapril trial provided data on the occurrence of clinical heart
failure, which the authors predefined as a clinically significant
decline in cardiac performance (Silber 2004). In the intervention
group, one participant (1%) developed such a significant decline,
while in the control group this occurred in six (9%) participants
(RR 0.16, 95% confidence interval (CI) 0.02 to 1.29; P = 0.09).
See also Analysis 1.1 and Figure 3.
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Figure 3. Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.1 Development of clinical heart
failure.
Occurrence of adverse events and tolerability (as
defined by authors)
Both studies reported on the occurrence of adverse events. Neither
study reported severity or grading.
In the enalapril trial, all participants were evaluated on the oc-
currence of adverse events (Silber 2004). The number of adverse
events in participants was presented per adverse event, and many
events were recorded (see Analysis 1.2 until Analysis 1.13 for RRs
and corresponding 95% CI, and Table 2 for Fisher’s exact P values
in outcomes with no event in one of the two groups). A notable
difference in adverse events between groups was the higher occur-
rence of dizziness or hypotension (RR7.17, 95%CI 1.71 to 30.17;
P = 0.007; Analysis 1.2; Figure 4) and fatigue (Fisher’s exact test,
P = 0.013; Table 2) in the enalapril group. Other reported adverse
events were not statistically different between groups (Analysis 1.3
until Analysis 1.13, and Table 2).
Figure 4. Forest plot of comparison: 1 Enalapril versus placebo, outcome: 1.2 Dizziness or hypotension.
In the phosphocreatine trial, all participants were also evaluated
for adverse events (Chen 2008), however it was not stated what
type of adverse events were assessed. No adverse events were found
in participants of either the phosphocreatine group or the control
group during the trial.
Change in cardiac function measured by a diagnostic
test
Both studies provided several measures of change in cardiac func-
tion in the treatment and control groups.
The enalapril trial presented their results in unadjusted and ad-
justed linear mixed models of the change over time of MCI,
LVESWS, SVI, and SF (Silber 2004). As the authors did not
present dichotomous outcomes, we were unable to calculate RRs
and therefore have described the outcomes as presented in the
original study (reported as ITT analyses). All analyses were ad-
justed for anthracycline dose, age at diagnosis, follow-up time,
gender, and cardiac irradiation. No differences were detected in
the rate of change of all outcome parameters between intervention
and control groups (adjusted model coefficient and P value of ef-
fect of enalapril: MCI 0.17, P = 0.36; LVESWS -1.41, P = 0.24;
SVI 0.004, P = 0.68; SF 0.07, P = 0.81). After the data became
available, the study authors explored the data and subsequently
performed a piecewise linear model on LVESWS. In this per-pro-
tocol analysis (adjusted for the same covariates) they found that
enalapril caused a decrease (that is improvement) in LVESWS (-
8.62 g/cm² change) compared with placebo (+1.66 g/cm² change)
in the first year of treatment (P = 0.036). After the first year there
was no statistically significant difference in LVESWS change be-
tween enalapril and placebo groups (-0.30 versus +0.49 g/cm², P
= 0.56).
In the phosphocreatine trial, complete baseline and outcome pa-
rameters were provided for echocardiographic cardiac function
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and the cardiac marker hsCRP (Chen 2008). All participants had
normal echocardiograms before and at the end of treatment (not
further specified). In the phosphocreatine group, mean (standard
deviation (SD)) baseline levels of hsCRP were 8.79 (1.36) mg/
L compared with 7.88 (2.08) mg/L in the control group, while
post-treatment levels were 2.23 (0.82) mg/L in the phosphocrea-
tine group compared with 4.2 (1.52) mg/L in the control group.
Since the SDs of the difference before and after treatment within
each group were not provided, we could not estimate the mean
difference. It is therefore unclear if the change in hsCRP was sig-
nificantly different between treatment groups. For the cardiac en-
zymes CK, CK-MB, LDH1, and alphaHBDH, only post treat-
ment levels were provided and are therefore not presented in this
review. For the outcomes ECG, troponin I and the combined
outcome of all cardiac enzymes together (hsCRP, CK, CK-MB,
LDH1, alphaHBDH, troponin I), numbers of participants with
normal or abnormal outcomes after the intervention were only
provided for those participants with abnormal values at baseline.
Since these outcomes were only assessed in a specific subgroup of
the studied cohort, we did not present them in this review.
(Duration of) hospitalisation for heart failure
None of the studies provided outcome data on the (duration of )
hospitalisation for heart failure.
Change in NYHA (New York Heart Association)
stage for heart failure
None of the studies provided change in NYHA stage for heart
failure as an outcome parameter.
The phosphocreatine trial did provide change in symptoms after
the intervention for the participants with symptoms at baseline
(Chen 2008). However, since this outcome was reported in less
than 50% of the participants, we did not present these data in this
review.
Change in quality of life (as defined by authors)
The enalapril study provided some information on quality of life
(Silber 2004). There were no differences between groups on any
of the dimensions of the Short-Form 36 General Health Survey or
the Childhood Health Questionnaire-85. No further information
was provided.
Costs as defined by authors
None of the included studies provided outcome data on costs.
D I S C U S S I O N
As a result of survival rates of childhood cancer patients now ap-
proximating 75%, there is a steadily growing group of young child-
hood cancer survivors who are faced with asymptomatic or even
symptomatic anthracycline-induced cardiac dysfunction. Many
collaborative groups have advocated screening for cardiac dys-
function in childhood cancer patients and survivors (Armenian
2014; Armenian 2015; COG 2006; Sieswerda 2012; SIGN 2013;
Skinner 2005). However, for appropriate screening for a disease,
an effective treatment should be available (Wilson 1968). In ad-
dition, physicians who are confronted with childhood cancer pa-
tients and survivors with cardiac dysfunction should be able to
make a well-informed decision regarding the risks and benefits
of treatment options. Although ACE inhibitors and beta-blockers
improve subclinical and clinical outcomes in adult populations
with symptomatic and asymptomatic cardiac dysfunction due to
other causes (Abdulla 2006; CIBIS-II 1999; Foody 2002; Garg
1995; Jong 2003; Packer 1996a; Packer 1996b; SOLVD 1991;
Waagstein 1993), the different aetiology makes it difficult to ex-
trapolate these beneficial effects to childhood cancer patients and
survivors with anthracycline-induced cardiotoxicity. This is an up-
date of the first systematic review, Sieswerda 2011, summarising
all evidence on medical interventions for anthracycline-induced
cardiotoxicity in childhood cancer patients and survivors.
For a reliable evaluation of the effects of medical interventions
for the treatment of anthracycline-induced cardiotoxicity, the best
study design is an RCT in which the only difference between the
intervention and control group is the use of the medical interven-
tion. However, because of the relative rareness of childhood cancer
and therefore of survivors with cardiac dysfunction, we expected
to find a low number of studies and therefore decided that both
RCTs and CCTs were eligible for this review, keeping in mind the
limitations of CCTs.
We identified two eligible RCTs investigating different medical
interventions in different study populations and with different
lengths of follow-up; in the update we identified no new studies.
Since for both medical interventions only one study was avail-
able, we could make no definitive conclusions about their effects
on anthracycline-induced cardiotoxicity. One RCT on enalapril
in childhood cancer survivors with asymptomatic anthracycline-
induced cardiotoxicity showed no significant effect of enalapril
on overall survival, mortality due to heart failure, development of
clinical heart failure, and quality of life compared with placebo
(Silber 2004). Only a post-hoc, per-protocol analysis done by the
study investigators themselves showed an improvement in a mea-
sure of cardiac function (LVESWS) in the enalapril group com-
pared with the placebo group in the first year of treatment. No
effect was found after one year for this or other echocardiographic
parameters of cardiac function over time. Participants treated with
enalapril had a higher risk of dizziness or hypotension and fatigue.
We could make no conclusions about the effect of enalapril on
(duration) of hospitalisation, change in NYHA stage of heart fail-
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ure, and costs, since these outcomes were not studied. The other
RCT, on phosphocreatine in children with acute leukaemia and
symptomatic or asymptomatic anthracycline-induced cardiotoxi-
city, showed no significant differences in overall survival, mortal-
ity due to heart failure, echocardiographic cardiac function, and
adverse events compared with a control treatment with vitamin
C, ATP, vitamin E, and oral coenzyme Q10 (in all outcomes no
events/abnormalities in both groups) (Chen 2008). The effect of
the intervention on one marker (hsCRP) was unclear. The study
did not report on development of clinical heart failure, (duration
of ) hospitalisation for heart failure, change in NYHA stage for
heart failure, or costs. We could therefore draw no conclusions for
these outcomes.
It should be noted that the reasons for not finding significant ben-
eficial effects in the enalapril trial could be due to the low num-
ber of participants (that is low power) and participant compliance
and loss to follow-up (Silber 2004). Also, the fact that there was a
low threshold for patients to be classified as having anthracycline-
induced cardiotoxicity could have influenced the identified effects
of treatment. Patients with minor and sometimes temporary ab-
normalities were included, in which large benefits of the interven-
tion were unlikely. In the SOLVD trial on enalapril in adults with
asymptomatic cardiac dysfunction due to other causes than an-
thracyclines (SOLVD 1992), a clear benefit of enalapril was found
on the occurrence of clinical heart failure. This trial had a much
larger sample size (4228 participants) and used a more strict def-
inition to classify patients as having cardiac dysfunction (that is
a left ventricular ejection fraction (LVEF) of 35% or less). The
enalapril trial had a relatively short length of follow-up (median
2.80 years). It is therefore unknown if there is a beneficial effect
of enalapril in the longer term. In comparison, a follow-up study
of the earlier mentioned SOLVD trial showed beneficial effects
of enalapril treatment on mortality during a 12-year follow-up
(Jong 2003; SOLVD 1992). In the phosphocreatine trial (Chen
2008), reasons for not identifying significant effects of the inter-
vention could also be the low power and the very short duration
of treatment and presumably also maximum follow-up (that is 14
days). Also, the most optimal dosage schedule of phosphocrea-
tine is currently unknown. Suboptimal dosages of study treatment
could have led to the finding of no differences between treatment
groups.
The enalapril study had a low/moderate risk of bias (Silber 2004).
There was a low/moderate risk of selection bias, performance bias,
and detection bias. For most outcomes there was a low risk of
attrition bias, but for some outcomes (the post-hoc analysis of
LVESWS, other parameters of cardiac function (SF and SVI),
change in quality of life, and risk of adverse events), ITT analysis
was not possible or it was unclear if follow-up was complete, lead-
ing to a possible risk of attrition bias for these other outcomes.
There were no other risks of bias, nor unexpected outcomes or
inconsistencies in the data. The phosphocreatine study had a high
risk of bias (Chen 2008). We concluded there was a high risk of
selection bias, performance bias, and detection bias. There was no
sign of attrition bias. There was a risk of reporting bias, and we had
concerns about the comparability of the two groups. We found no
unexpected outcomes or other inconsistencies in the data.
The external validity of a study indicates how well the results of
the study can be generalised to individual patients with anthracy-
cline-induced cardiotoxicity during and after treatment for child-
hood cancer. Although we did not systematically assess this in this
review, we regarded the external validity of the enalapril trial as
reasonable (Silber 2004). Participant characteristics were well-de-
fined, and the study population seemed to be a representative sam-
ple of childhood cancer survivors who can present with asymp-
tomatic cardiotoxicity during follow-up. However, it should be
noted that a large proportion of participants had been treated pre-
viously with cardiac radiotherapy. It is not unlikely that the patho-
physiology, course, and response to treatment of cardiac dysfunc-
tion that is induced by both anthracyclines and radiotherapy is
different from cardiac dysfunction caused by anthracyclines only.
In addition, other study characteristics could have influenced the
effects of treatment. An observational study in adults with anthra-
cycline-induced cardiotoxicity suggested that time between the
end of anthracycline treatment and start of heart failure treatment
(including at least enalapril) influenced the chance of response to
ACE inhibitors, with a longer follow-up time associated with a
lower chance of a beneficial effect (Cardinale 2010). Another is-
sue regarding the generalisability of the enalapril trial is that the
diagnostic tools to determine cardiotoxicity that were used in this
study are not easily used in daily practice. Especially equipment
and expertise to determine MCI, LVESWS, and SVI may not be
widely available in the follow-up settings of childhood cancer sur-
vivors. As previously mentioned, the duration of follow-up pre-
cludes extrapolation to follow-up longer than three years. Finally,
clear outcome definitions were provided, making it easy to ex-
trapolate the study outcomes to daily practice. The phosphocrea-
tine trial was less well generalisable to daily practice (Chen 2008).
Not all participant characteristics were described, including age
and gender of the control group, time since leukaemia diagno-
sis, and information on (previous) cardiotoxic cancer treatment.
No clear definitions (that is cutoff values of abnormal diagnos-
tic tests) of cardiotoxicity were provided. No participant had an
abnormal echocardiogram, and since most research on anthracy-
cline-induced cardiotoxicity, as well as guidelines on detection of
cardiotoxicity, include echocardiographic examination of child-
hood cancer patients and survivors, we feel that the study group is
not very representative with regard to cardiotoxicity (COG 2006;
SIGN 2013; Skinner 2005; Steinherz 1992; Van Dalen 2006b).
In addition, phosphocreatine is an experimental therapy and not a
registered agent at the European Medicines Agency (EMA) or US
Food and Drug Administration (FDA). Both the intervention and
the control treatments are not common practice inmost countries.
Treatment duration and outcome assessment of cardiac function
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in this trial were only two weeks, so we only know the immediate
effects of the intervention studied and not any long-term benefits
or harms. Based on these arguments, we feel that the outcomes of
the phosphocreatine trial can hardly be extrapolated to daily clin-
ical practice and care for childhood cancer patients (Chen 2008).
There was no evidence available from RCTs or CCTs for other
medical interventions for treating anthracycline-induced symp-
tomatic and asymptomatic cardiotoxicity during and after treat-
ment for childhood cancer (for a complete list of evaluated in-
terventions, see the search strategy in Appendix 1; Appendix 2;
Appendix 3).
Please note that in this review RCTs and CCTs were only eligi-
ble for inclusion when the participants (previously) had a type of
childhood cancer (defined as a diagnosis of cancer at age 18 years
or younger). RCTs or CCTs including both children and adults
were only eligible for inclusion in this review if themajority of par-
ticipants were 18 years or younger at cancer diagnosis. It is possible
that there are RCTs or CCTs in adults that evaluate the effects of
medical interventions on anthracycline-induced cardiotoxicity in
cancer patients or survivors. We did not systematically search for
trials in adults, but we noted that there was anRCTon enalapril for
treating adults with evidence of cardiotoxicity (as indicated by ele-
vated troponin I) after high-dose chemotherapy (which contained
anthracycline in most participants) (Cardinale 2006). This trial
found that participants treated with enalapril were significantly
less likely to experience decline of left ventricular ejection frac-
tion by 10% compared with untreated participants during one-
year follow-up. There is another ongoing RCT of ranolazine for
treatment of diastolic dysfunction in adults who completed stan-
dard dose chemotherapy for Hodgkin lymphoma, breast cancer,
or colorectal cancer (Minotti 2013). However, this RCT is only
aimed at short-term evaluation of cardiac function parameters and
biomarkers and will unlikely inform the efficacy of ranolazine in
long-term, patient-oriented outcomes such as mortality or cardiac
events. There were also some non-controlled observational stud-
ies on adults with anthracycline-induced cardiotoxicity (Cardinale
2010; Jensen 1996; Jensen 2002;Noori 2000; Tallaj 2005; Thakur
2014;Vatutin 2001).One of these studies evaluatedACE inhibitor
(with or without a beta-blocker) treatment in all study participants
(Cardinale 2010). This study was a prospective cohort study with
a mean follow-up of 36 months in 201 adults with symptomatic
and asymptomatic cardiac dysfunction after anthracycline ther-
apy, who were all treated with at least an ACE inhibitor as soon as
cardiac impairment was noted. The study showed a (prespecified)
response of cardiac function in 42%, a partial response in 13%,
and no response in 45% of the study group. Responders had fewer
cardiac events, and the study found a relationship between the du-
ration of cardiac dysfunction and the probability of response to the
therapy. The authors did not report if side effects occurred. It was
concluded that beneficial effects of modern heart failure treatment
are expected when treatment is started early after the detection
of anthracycline-induced cardiotoxicity. It should be noted that
it is not always appropriate to extrapolate adult cancer (survivor)
studies to childhood cancer (survivor) studies. Other age ranges,
pharmacokinetics, pharmacodynamics, as well as comorbidities
and co-treatments may influence the effect of interventions for
cardiotoxicity as well as the generalisability of studies to the clinical
care of childhood cancer patients and survivors. Similarly, RCTs
in other childhood populations are also difficult to generalise to
childhood cancer patients and survivors. For example, in an RCT
of the beta-blocker carvedilol in children with symptomatic heart
failure (Shaddy 2007), almost 40% of the study population had
symptomatic heart failure due to congenital heart disease, with
often a very different anatomy of the heart.
Even though RCTs provide the highest levels of evidence, observa-
tional studies can sometimes be useful when no, or few, RCTs or
CCTs are available. A retrospective cohort study described clinical
and echocardiographic follow-up of 18 childhood cancer survivors
with symptomatic and asymptomatic anthracycline-induced car-
diotoxicity from the start of enalapril treatment during a median
follow-up of 10 years (Lipshultz 2002). There were no serious side
effects during the long-term enalapril treatment in the cohort. The
authors found an initial improvement of cardiac function, but a
deterioration of cardiac function and clinical parameters after six
years of follow-up. However, the study was small, had no con-
trol group, and is highly prone to selection, detection, and perfor-
mance bias. Another retrospective study of childhood cancer sur-
vivors treated with anthracyclines compared a group of 34 growth
hormone (GH)-treated children to a group of 86 children not
treated with GH therapy (Lipshultz 2005b). Echocardiographic
assessments performed during routine clinical follow-up were re-
analysed by an investigator blinded for the intervention. From re-
peated measurements analyses adjusted for baseline characteristics
and non-random missingness of data, the authors’ main conclu-
sion was that GH therapy increased left ventricular wall thickness
during but not after therapy. It should be noted that among other
issues, the retrospective construction of the control group, several
confounding factors that were not adjusted for (such as co-treat-
ment with cardiovascular medication), and missing outcome data
for a large part of the two groups, put this study at high risk for
selection and attrition bias. We can therefore draw no (careful)
conclusions from these two observational studies.
We are awaiting the results of the ongoing study (NCT00003070),
as well as more information from the two studies for which
we could not obtain enough information for inclusion (see
Characteristics of studies awaiting classification table). There was
no new information about this ongoing study and two studies
awaiting classification during the update of the review.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
We identified one RCT comparing enalapril and placebo in child-
hood cancer survivors with asymptomatic cardiotoxicity (Silber
2004). Although there is some evidence that enalapril temporarily
improves one parameter of cardiac function (LVESWS), the cur-
rent evidence did not show a statistically significant improvement
of other parameters of cardiac function nor of clinical outcomes
such as overall survival, mortality due to heart failure, occurrence
of clinical heart failure, and quality of life. However, ’no evidence
of effect’ should not be confused with ’evidence of no effect’. The
RCT showed that enalapril treatment is associated with a higher
risk of dizziness or hypotension and fatigue. Effects of enalapril
on (duration of ) hospitalisation, change in NYHA stage of heart
failure, and costs were not studied. Also, no evidence was available
on the effects of enalapril beyond 2.8 years of follow-up and on
treating symptomatic cardiotoxicity. Based on the currently avail-
able evidence in childhood cancer survivors with asymptomatic
anthracycline-induced cardiac dysfunction, we are not able to pro-
vide appropriate recommendations for clinical practice. Clinicians
should weigh the potential benefits of enalapril with the known
side effects in childhood cancer survivors with asymptomatic an-
thracycline-induced cardiac dysfunction.
We identified one RCT comparing phosphocreatine and a control
treatment of vitamin C, ATP, vitamin E, and oral coenzyme Q10
in childhood leukaemia patients with symptomatic and asymp-
tomatic cardiotoxicity (Chen 2008). Limited data with a high risk
of bias and poor generalisability showed no difference of phos-
phocreatine compared with a control treatment on overall sur-
vival, mortality due to heart failure, echocardiographic function,
and adverse events. The effect of the intervention on one marker
(hsCRP) was unclear, and effects on occurrence of clinical heart
failure, (duration) of hospitalisation, change in NYHA stage of
heart failure, and costs were not studied. No evidence was available
of the effects of phosphocreatine beyond two weeks of treatment
or on the effects of phosphocreatine in survivors of childhood can-
cer with symptomatic or asymptomatic cardiotoxicity. Based on
the currently available evidence, we do not recommend the use of
phosphocreatine in clinical practice.
We identified no RCTs or CCTs studying other medical interven-
tions for symptomatic or asymptomatic cardiotoxicity in child-
hood cancer patients or survivors. We can therefore make no con-
clusions about the effect of other medical interventions in these
patients and are unable to provide appropriate recommendations
for clinical practice.
Implications for research
One RCT has studied the effect of enalapril in childhood cancer
survivors with asymptomatic anthracycline-induced cardiac dys-
function and found no clear effect on clinical outcomes, possibly
due to, among other things, low power of the study (Silber 2004).
As there is strong evidence that ACE inhibitors are beneficial for
asymptomatic cardiac dysfunction in other populations, we urge
the scientific community to start high-quality studies evaluating
the effect of enalapril in childhood cancer patients and survivors
with symptomatic or asymptomatic anthracycline-induced car-
diotoxicity. These studies should preferably be RCTs, within ho-
mogenous populations and with long-term follow-up using valid
and clinically relevant selection criteria and outcome definitions.
Previous treatment with radiotherapy, duration since cancer diag-
nosis, duration of cardiotoxicity, the age of the patient, the severity
of cardiotoxicity, and comorbidity should ideally be taken into ac-
count. The number of included participants should be sufficient
for the power that is needed for reliable results. In addition, a long-
term follow-up study of the enalapril trial (Silber 2004), evalu-
ating the long-term effects of enalapril treatment versus placebo,
would be very contributory to the current evidence.
One low-quality RCT has studied the effect of phosphocreatine
in childhood leukaemia patients with symptomatic or asymp-
tomatic anthracycline-induced cardiac dysfunction (Chen 2008).
Other medical interventions for symptomatic or asymptomatic
cardiotoxicity in childhood cancer patients or survivors have not
been studied in RCTs or CCTs, even though several potentially
beneficial treatment options are available. Evidence on potential
treatments for this severe complication is especially needed for
symptomatic childhood cancer patients and survivors, therefore,
studies with the above-mentioned criteria should also be started
evaluating different treatment options in childhood cancer pa-
tients and survivors with symptomatic cardiotoxicity.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chen 2008
Methods RCT using simple random allocation to intervention and control groups
Participants 68 childhood cancer patients, receiving phosphocreatine or control treatment of a com-
bination of vitamin C, ATP, vitamin E, and coenzyme Q10
Included participants had anthracycline-related cardiotoxicity based on cardiac enzymes
(CK, CK-MB, LDH1, alphaHBDH, troponin I, hsCRP), ECG and/or echocardiogram
Median (range) age of the phosphocreatine group was 5 (1 to 15) years; 15 of 35 were
males. Age and gender of the control group were not mentioned. Median time since
cancer diagnosis was not mentioned. Participants had a diagnosis of acute lymphatic
leukaemia or acute myeloid leukaemia
For both groups information on (previous) cardiotoxic cancer treatment (cumulative
anthracycline dose, cardiac radiotherapy and dose, and cardioprotective interventions)
was not mentioned. Other cardiovascular comorbidities and treatments were also not
mentioned
At the start of the study, distribution of abnormalities in cardiac symptoms and signs
in the treatment group (n = 35) was: cardiac symptoms 18, abnormal cardiac enzymes
28, abnormal troponin I 7, abnormal ECG 20, and abnormal echocardiogram 0. Mean
(SD) hsCRP in the treatment group was 8.79 (1.36) mg/L. For the control group (n =
33) this distribution was: cardiac symptoms 16, abnormal cardiac enzymes 25, abnormal
troponin I 7, abnormal ECG 18, and abnormal echocardiogram 0. Mean (SD) hsCRP
in the control group was 7.88 (2.08) mg/L. Time since diagnosis of cardiotoxicity was
not mentioned
Interventions Phosphocreatine 1 g intravenously over 30 to 40 minutes once to twice per day (n = 35)
or a combination treatment of vitamin C 150 mg/kg and ATP 20 mg into 5% glucose
100ml intravenously once per day, oral vitamin E 50mg once per day, and oral coenzyme
Q10 (ubidecarenone) 10 mg 3 times per day. All treatment durations were 14 days
Outcomes Overall survival.
Mortality due to heart failure (no definitions provided).
Occurrence of adverse events (no definition provided).
Change in cardiac function (normal/abnormal echocardiography, change in hsCRP,
normal/abnormal ECG, normal/abnormal cardiac enzymes (CK, CK-MB, LDH1, al-
phaHBDH, troponin I, and hsCRP), postintervention levels of CK, CK-MB, LDH1,
alphaHBDH, and troponin I. No definitions were provided)
Notes The abstract (in English) mentions “retrospectively assessed”. However, we think the
study is an RCT, because there is a statement in the methods section (in Chinese) that
“all patients have entered the clinical trial with simple random allocation to treatment
and control groups.”
Duration of follow-up was not mentioned, but it seems that it was 15 days for the
assessment of cardiac function, since that was done at the beginning and one day after
the intervention. For clinical outcomes this was unclear. There was no loss to follow-up
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Chen 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding of participants? High risk Blinding of participantswas notmentioned
but seemed inadequate or very unlikely
since the intervention and control treat-
ment haddifferent routes of administration
Blinding of personnel? High risk Blinding of personnel was not mentioned
but seemed inadequate or very unlikely
since the intervention and control treat-
ment haddifferent routes of administration
Blinding of outcome assessors?
Mortality due to heart failure
Unclear risk Blinding of outcome assessors was not
mentioned
Blinding of outcome assessors?
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Unclear risk Blinding of outcome assessors was not
mentioned
Blinding of outcome assessors?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Unclear risk Blinding of outcome assessors was not
mentioned
Completeness of follow-up
Overall survival
Low risk Outcome could be abstracted for all partic-
ipants
Completeness of follow-up
Mortality due to heart failure
Low risk Outcome could be abstracted for all partic-
ipants
Completeness of follow-up
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Low risk Outcome was provided for all participants
Completeness of follow-up
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For echocardiography (normal/abnormal)
change in outcomewas provided for all par-
ticipants
Completeness of follow-up
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For 1 biomarker (hsCRP) change in out-
come was provided for all participants
Intention-to-treat-analysis?
Overall survival
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Mortality due to heart failure
Low risk Allocation was provided for the reported
outcome
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Chen 2008 (Continued)
Intention-to-treat-analysis?
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For echocardiography (normal/abnormal)
treatment allocation was provided
Intention-to-treat-analysis?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For the biomarker (hsCRP) treatment allo-
cation was provided
Free of selective reporting? Unclear risk We found no published protocol in which
the reported outcomes and analyses were
prespecified
Free of other bias? High risk The baseline characteristics were not fully
described. For example, there was no data
about the gender and age distributionof the
control group. We do not know what type
of anthracycline and what doses of medi-
cations were used in each group, and we
have no information on whether radiation
therapy was given. We are therefore uncer-
tain whether the intervention and control
groups were comparable/similar at baseline
We are uncertain whether co-interventions
were different between the intervention
and control groups
Random sequence generation? Unclear risk No description of sequence generation
Allocation concealment? Unclear risk No description of allocation concealment
Silber 2004
Methods ACE inhibitor After Anthracycline (AAA) trial. Double-blinded RCT. Randomisations
were performed using random permuted blocks (random size between 2 and 8) with
equal allocation to each treatment (stratified according to the variables age at treatment
(under 3 years old versus 3 years or older), total cumulative anthracycline dose (under
300 mg/m² versus 300 mg/m² or higher), and time from diagnosis (less than 10 years
versus 10 years or more))
Participants 135 childhood cancer survivors (aged 8.3 to 30.6 years, 78 males) with asymptomatic
decline of cardiac function at some time after anthracycline exposure, detected with
echocardiography, resting or exercise GNA, MCI at peak exercise, and/or resting ECG
Median (range) time since cancer diagnosis 9 (4.2 to 22.3) years in the enalapril group
and 9.6 (4.3 to 25.8) years in the placebo group. Participants had been treated for various
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Silber 2004 (Continued)
types of cancer diagnosis at a median (range) age of 7.2 (3 to 21.8) years in the enalapril
group and 8.2 (0.3 to 10.3) years in the placebo group.Median (range) age at study entry
was 17 (8.3 to 31.5) years in enalapril group and 18.9 (8.1 to 30.6) years in placebo
group
Previous anthracycline treatment with median (range) cumulative anthracycline dose
305 (75 to 396) mg/m² in enalapril group and 300 (75 to 738) mg/m² in placebo
group (types of anthracyclines not mentioned). Previous cardiac radiotherapy in enalapril
group: 26 (38%), unknown in 1 (1.4%). In placebo group: 23 (35%), unknown in 0
(0%). Other previous potential cardiotoxic treatment or cardioprotective interventions
not mentioned. Total radiotherapy dose, other cardiovascular comorbidities, and treat-
ments were not mentioned. 1 participant in enalapril group required a growth hormone
supplement and 1 participant in placebo group required a testosterone supplement.
At the start of the study, 111 participants had echocardiographic abnormalities (based on
SF, LVESWS, and/or SVI) and/or abnormalities during resting or exercise GNA (based
on EF). Of the remaining 24 participants, 7 had (only) abnormalities on cycle ergometry
(based on MCI), and 17 had any of the abnormalities (possibly including an abnormal
QTc interval on ECG) before study entry.Mean (SD) cardiac function in enalapril group
was: MCI (L/min/m²): 8.39 (2.66) (68 participants), LVESWS (g/cm²): 73.2 (19.0) (69
participants), EF (%): 59.1 (7.4) (69 participants), SF (%): 30.7 (4.9) (69 participants)
, QTc (ms): 418 (23.4) (69 participants). Mean (SD) cardiac function in placebo group
was: MCI (L/min/m²): 8.24 (2.57) (65 participants), LVESWS (g/cm²): 68.4 (20.4) (66
participants), EF (%): 58.3 (7.1) (64 participants), SF (%): 30.6 (3.9) (66 participants),
QTc (ms): 411 (17.6) (66 participants). Time since diagnosis of cardiotoxicity was not
mentioned
Interventions Oral enalapril once daily (n = 69) or oral placebo once daily (n = 66). Dosing of study
medication was as follows: at start 0.05 mg/kg/day, escalation after 14 days to 0.10 mg/
kg/day, and escalation at 3-months visit to 0.15 mg/kg/day if no side effects occurred
Outcomes Overall survival.
Mortality due to heart failure (no definitions provided).
Development of clinical heart failure (defined as a clinically significant decline in cardiac
performance: documented acute congestive heart failure, SF decline 20% (and below
28%) from baseline in 2 measures or MCI decline by 30% (and 2 SD below the mean)
from baseline in 2 measures)
Occurrence of adverse events (no definition provided).
Change in cardiac function (Primary outcome: rate of decline over time of MCI. Sec-
ondary outcome: rate of increase over time in LVESWS. Other outcomes: first-year re-
duction in LVESWS (post-hoc and ITT analysis), % change in SF and change in SVI
over time)
Quality of life: based on the Short-Form 36 General Health Survey (age above 14 years)
or the Childhood Health Questionnaire-85 (age equal to or younger than 14 years). No
definition for an abnormal outcome was provided
Notes Median (range) follow-up time was 2.80 years (2 weeks to 6.1 years). Loss to follow-up
was not mentioned
Since the authors did not present dichotomous outcomes, we were not able to define RRs
for the outcome change in cardiac function; we have therefore described the outcomes
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Silber 2004 (Continued)
as presented in the original study
Risk of bias
Bias Authors’ judgement Support for judgement
Blinding of participants? Low risk Participants were effectively blinded to the
intervention
Blinding of personnel? Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the personnel were effectively blinded
Blinding of outcome assessors?
Mortality due to heart failure
Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the outcome assessors were effectively
blinded
Blinding of outcome assessors?
Development of clinical heart failure (as de-
fined by authors)
Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the outcome assessors were effectively
blinded
Blinding of outcome assessors?
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the outcome assessors were effectively
blinded
Blinding of outcome assessors?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the outcome assessors were effectively
blinded
Blinding of outcome assessors?
Change in quality of life (as defined by au-
thors)
Low risk Investigators were blinded to the interven-
tion. Based on this statement and the ef-
fective blinding of participants, we judged
that the outcome assessors were effectively
blinded
Completeness of follow-up
Overall survival
Low risk Outcome could be abstracted from all par-
ticipants
Completeness of follow-up
Mortality due to heart failure
Low risk Outcome could be abstracted from all par-
ticipants
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Silber 2004 (Continued)
Completeness of follow-up
Development of clinical heart failure (as de-
fined by authors)
Low risk Outcome was provided for all participants
Completeness of follow-up
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Unclear risk Completeness of follow-up not mentioned
Completeness of follow-up
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For MCI, any follow-up measurement was
done in 83% of the participants. Com-
pleteness of follow-up at the end of the
study was not mentioned
Completeness of follow-up
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For LVESWS, follow-up was 93% in the
first year. Follow-up after the first year was
not mentioned
Completeness of follow-up
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Unclear risk For other outcomes of cardiac function (SF
and SVI), completeness of follow-up was
not mentioned
Completeness of follow-up
Change in quality of life (as defined by au-
thors)
Unclear risk Completeness of follow-up not mentioned
Intention-to-treat-analysis?
Overall survival
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Mortality due to heart failure
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Development of clinical heart failure (as de-
fined by authors)
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Occurrence of adverse events and tolerabil-
ity (as defined by authors)
Low risk Allocation was provided for the reported
outcome
Intention-to-treat-analysis?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Low risk For change in MCI and LVESWS, study
authors performed intention-to-treat-anal-
yses
Intention-to-treat-analysis?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
High risk For the extra post-hoc analysis of change in
LVESWS (piecewise model), study authors
performed a per-protocol analysis
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Silber 2004 (Continued)
Intention-to-treat-analysis?
Change in cardiac function measured by a
diagnostic test (as defined by authors)
Unclear risk For other outcomes of cardiac function (SF
and SVI), it was not stated if intention-to-
treat-analyses were performed
Intention-to-treat-analysis?
Change in quality of life (as defined by au-
thors)
Low risk Allocation was provided for the reported
outcome
Free of selective reporting? Low risk There was a published protocol in which
the reported outcomes and analyses were
prespecified. All outcomes were reported
and the analyses were done in the final
report. The authors clearly explained that
they had performed some additional anal-
yses based on exploration of the data
Free of other bias? Low risk No other bias was identified
Random sequence generation? Low risk Randomisationswere performedusing ran-
dom permuted blocks (random size be-
tween2 and8)with equal allocation to each
treatment
Allocation concealment? Unclear risk It was stated that there was allocation con-
cealment, but the method of allocation
concealment was not mentioned
alphaHBDH: alpha hydroxybutyrate dehydrogenase
ATP: adenosine triphosphate
CK: creatine kinase
CK-MB: creatine kinase MB
ECG: electrocardiogram
EF: ejection fraction
GNA: gated nuclear angiography
hsCRP: hyper-sensitivity C-reactive protein
ITT: intention-to-treat
LDH1: lactate dehydrogenase
LVESWS: left ventricular end-systolic wall stress
MCI: maximal cardiac index
RCT: randomised controlled trial
RR: risk ratio
SD: standard deviation
SF: shortening fraction
SVI: stress-velocity index
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Garcia 2007 Not RCT or CCT
Ginsberg 2004 Health-related quality of life was assessed in participants of the AAA trial (Silber 2004), but outcomes were not
related to the treatment allocation
Shaddy 2007 In consultation with the authors of the paper: people with anthracycline-induced cardiomyopathy were included in
the trial, but it was not possible to separate the data of these participants from the data of all included participants
Tallaj 2005 Not RCT or CCT
Vatutin 2001 Exclusion based on adult age
AAA trial: ACE inhibitor After Anthracycline trial
CCT: controlled clinical trial
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Mandric 2008
Methods CCT comparing enalapril to placebo
Participants 30 survivors of paediatric haematological malignancies, aged between 6 and 14 years and treated with doxorubicin.
All participants had at least 1 cardiac abnormality identified at any time after anthracyclines exposure
Enalapril group: 10 children, mean age at diagnosis 6 years, mean or median follow-up 16 months
Placebo group: 20 children. Mean age and follow-up not mentioned
Both groups hadbeen treatedwith similar doses of anthracyclines.No further participant characteristicswere provided.
Duration of follow-up was unclear
Interventions Enalapril (dose range between 0.2 and 0.5 mg/kg/day)
Placebo (not further specified)
Outcomes Cardiac evaluation (including echocardiography) at baseline and at 3, 6, 12, 16 months after initiation of enalapril/
placebo therapy
In the enalapril group, progressive improvement in LV dimensions (end-systolic and end-diastolic), fractional short-
ening, LV mass, LV per cent posterior wall thickening, interventricular per cent septal thickening, and Tei index was
found
In the placebo group, the same echocardiographic parameters were constant or worsened in the course of follow-up
(not further specified)
Notes This study has not been published in full text, but was presented at the SIOP conference 2008 (abstract L.030). It
seems that children were not randomised. Completeness of follow-up was not mentioned
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Mandric 2009
Methods Unclear (possibly a CCT)
Participants 27 children aged between 3 and 18 years
Enalapril group: 10 children with subclinical cardiotoxicity on echocardiography
No “cardioprotector” group: 6 children with a chemotherapeutic protocol completed. It was not specified if this
group suffered from cardiotoxicity
Newly diagnosed group: 11 children with newly diagnosed cancer. It was not specified if this group received an
intervention
No further participant characteristics were provided. Duration of follow-up was unclear
Interventions Enalapril (not further specified)
No “cardioprotector” (not further specified)
Outcomes Periodic history and physical examination, electrocardiogram, chest X-ray, 2-dimensional/Doppler echocardiography,
cardiac biomarkers (BNP, cTnI, ALAT, CPK)
“Clinical manifestations”: heart failure: 1 participant; “untypical manifestation”: 15 participants; “echocardiographic
modifications”: 6 participants; electrocardiographic changes: 5 participants; high values of plasma BNP (cutoff value
of 100 microgram/ml): 11 participants
The differences in these outcomes between subgroups were not mentioned, except that all children on “cardiopro-
tector” treatment had normal values of BNP and cTnI
Notes This study has not been published in full text, but was presented at the SIOP conference 2009 (abstract PQ.020).
The title suggested that cardiotoxicity in children in the “no cardioprotector group” (and possibly also in the “newly
diagnosed group”) was caused by anthracyclines. It seems that participants were not randomised. Completeness of
follow-up was not mentioned
ALAT: alanine transaminase
BNP: brain natriuretic peptide
CCT: controlled clinical trial
CPK: creatine phosphokinase
cTnI: cardiac troponin I
LV: left ventricular
SIOP: Société Internationale d’Oncologie Pédiatrique (International Society of Paediatric Oncology)
Characteristics of ongoing studies [ordered by study ID]
NCT00003070
Trial name or title Afterload reduction therapy for late anthracycline cardiotoxicity: a pediatric oncology group cancer control
study
Methods Randomised, double-blinded, phase III trial to compare the effectiveness of enalapril with a placebo in treating
heart damage in people who received anthracycline chemotherapy for childhood cancer
Participants People with histologically diagnosed childhoodmalignancy who had prior anthracycline therapy and echocar-
diographic evidence of reduced fractional shortening, reduced contractility, or increased afterload, or any
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NCT00003070 (Continued)
combination of these. At least 6 months oncologic disease-free. At least 8 years old at study entry and less
than 22 years at diagnosis. At least 1 year since prior cumulative anthracycline therapy of at least 200 mg/m²
Interventions Enalapril maleate and placebo
Outcomes Body surface area-adjusted left ventricular mass, ventricular function, quality of life
Starting date 15 August 1997
Contact information Stephen Lipshultz, James P. Wilmot Cancer Center
Notes On the ongoing-trial website there is a note about the recruitment status: completed. However, we found no
publication of this trial. One of the review authors (LK) learned from contacts in the US that this trial has as
yet not been executed
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D A T A A N D A N A L Y S E S
Comparison 1. Enalapril versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development of clinical heart
failure
1 135 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.02, 1.29]
2 Dizziness or hypotension 1 135 Risk Ratio (M-H, Random, 95% CI) 7.17 [1.71, 30.17]
3 Rash or hives 1 135 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.25, 3.67]
4 Heart palpitations 1 135 Risk Ratio (M-H, Random, 95% CI) 3.83 [0.44, 33.35]
5 Anxiety or depression 1 135 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.18, 20.60]
6 Headache 1 135 Risk Ratio (M-H, Random, 95% CI) 3.83 [0.44, 33.35]
7 Gastrointestinal disturbance 1 135 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.20, 4.57]
8 Hepatitis C 1 135 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.11, 3.70]
9 Neutropenia 1 135 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.04, 5.15]
10 Musculoskeletal pain 1 135 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.20, 4.57]
11 Dry cough 1 135 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.06, 14.98]
12 Shortness of breath 1 135 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.14, 6.59]
13 Chest pain 1 135 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.51, 5.45]
Analysis 1.1. Comparison 1 Enalapril versus placebo, Outcome 1 Development of clinical heart failure.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 1 Development of clinical heart failure
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 1/69 6/66 100.0 % 0.16 [ 0.02, 1.29 ]
Total (95% CI) 69 66 100.0 % 0.16 [ 0.02, 1.29 ]
Total events: 1 (Enalapril), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
30Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for
childhood cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Enalapril versus placebo, Outcome 2 Dizziness or hypotension.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 2 Dizziness or hypotension
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 15/69 2/66 100.0 % 7.17 [ 1.71, 30.17 ]
Total (95% CI) 69 66 100.0 % 7.17 [ 1.71, 30.17 ]
Total events: 15 (Enalapril), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.3. Comparison 1 Enalapril versus placebo, Outcome 3 Rash or hives.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 3 Rash or hives
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 4/69 4/66 100.0 % 0.96 [ 0.25, 3.67 ]
Total (95% CI) 69 66 100.0 % 0.96 [ 0.25, 3.67 ]
Total events: 4 (Enalapril), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours enalapril
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Analysis 1.4. Comparison 1 Enalapril versus placebo, Outcome 4 Heart palpitations.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 4 Heart palpitations
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 4/69 1/66 100.0 % 3.83 [ 0.44, 33.35 ]
Total (95% CI) 69 66 100.0 % 3.83 [ 0.44, 33.35 ]
Total events: 4 (Enalapril), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.5. Comparison 1 Enalapril versus placebo, Outcome 5 Anxiety or depression.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 5 Anxiety or depression
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 2/69 1/66 100.0 % 1.91 [ 0.18, 20.60 ]
Total (95% CI) 69 66 100.0 % 1.91 [ 0.18, 20.60 ]
Total events: 2 (Enalapril), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
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Analysis 1.6. Comparison 1 Enalapril versus placebo, Outcome 6 Headache.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 6 Headache
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 4/69 1/66 100.0 % 3.83 [ 0.44, 33.35 ]
Total (95% CI) 69 66 100.0 % 3.83 [ 0.44, 33.35 ]
Total events: 4 (Enalapril), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.7. Comparison 1 Enalapril versus placebo, Outcome 7 Gastrointestinal disturbance.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 7 Gastrointestinal disturbance
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 3/69 3/66 100.0 % 0.96 [ 0.20, 4.57 ]
Total (95% CI) 69 66 100.0 % 0.96 [ 0.20, 4.57 ]
Total events: 3 (Enalapril), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
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Analysis 1.8. Comparison 1 Enalapril versus placebo, Outcome 8 Hepatitis C.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 8 Hepatitis C
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 2/69 3/66 100.0 % 0.64 [ 0.11, 3.70 ]
Total (95% CI) 69 66 100.0 % 0.64 [ 0.11, 3.70 ]
Total events: 2 (Enalapril), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.9. Comparison 1 Enalapril versus placebo, Outcome 9 Neutropenia.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 9 Neutropenia
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 1/69 2/66 100.0 % 0.48 [ 0.04, 5.15 ]
Total (95% CI) 69 66 100.0 % 0.48 [ 0.04, 5.15 ]
Total events: 1 (Enalapril), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
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Analysis 1.10. Comparison 1 Enalapril versus placebo, Outcome 10 Musculoskeletal pain.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 10 Musculoskeletal pain
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 3/69 3/66 100.0 % 0.96 [ 0.20, 4.57 ]
Total (95% CI) 69 66 100.0 % 0.96 [ 0.20, 4.57 ]
Total events: 3 (Enalapril), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.11. Comparison 1 Enalapril versus placebo, Outcome 11 Dry cough.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 11 Dry cough
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 1/69 1/66 100.0 % 0.96 [ 0.06, 14.98 ]
Total (95% CI) 69 66 100.0 % 0.96 [ 0.06, 14.98 ]
Total events: 1 (Enalapril), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
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Analysis 1.12. Comparison 1 Enalapril versus placebo, Outcome 12 Shortness of breath.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 12 Shortness of breath
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 2/69 2/66 100.0 % 0.96 [ 0.14, 6.59 ]
Total (95% CI) 69 66 100.0 % 0.96 [ 0.14, 6.59 ]
Total events: 2 (Enalapril), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
Analysis 1.13. Comparison 1 Enalapril versus placebo, Outcome 13 Chest pain.
Review: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Comparison: 1 Enalapril versus placebo
Outcome: 13 Chest pain
Study or subgroup Enalapril Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Silber 2004 7/69 4/66 100.0 % 1.67 [ 0.51, 5.45 ]
Total (95% CI) 69 66 100.0 % 1.67 [ 0.51, 5.45 ]
Total events: 7 (Enalapril), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours enalapril Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Criteria list for the assessment of risk of bias of included studies
Item ID Description Implementation
Selection bias
a Was the allocation sequence adequately generated? Adequate when a random (and therefore unpredictable) se-
quence was used to allocate the intervention to the partici-
pants
b Was allocation adequately concealed? Adequate when the upcoming allocations of participants
were masked from those involved in enrolment into the trial
Performance bias
c Was knowledge of the allocated intervention by participants
adequately prevented during the study?
Adequate when the participants were unaware of the inter-
vention they received
d Was knowledge of the allocated intervention by personnel ade-
quately prevented during the study?
Adequate when the personnel involved in the care of the
participants were unaware of the intervention a participant
received
Detection bias (for each outcome separately)
e Was knowledge of the allocated intervention by the outcome
assessor adequately prevented during the study?
Adequate when the outcome assessor was unaware of the
intervention a participant received
Attrition bias (for each outcome separately)
f Was the follow-up of the outcome complete? Complete when the outcome was assessed in at least 80%
of the study cohort
g Was an intention-to-treat-analysis performed? Adequate when all participants were analysed in the treat-
ment group to which they were randomised, regardless of
whether or not they received the allocated intervention
Reporting bias
h Are reports of the study free of the suggestion of selective outcome
reporting?
Adequate when a study protocol was available that prespec-
ified study outcomes and analyses, which were all reported
in the final study report
Other sources of bias
i Was the study apparently free of other problems that could put
it at a high risk of bias?
Adequate when there were no other important personal con-
cerns about bias not addressed in the other domains in the
tool
All items were scored yes, no, or unclear.
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Table 2. Fisher’s exact test of outcomes with no events in the enalapril or placebo group
Outcome Enalapril (n = 69) Placebo (n = 66) P value
Dehydration 0 1 0.49
Fatigue 7 0 0.013
Fever 0 1 0.49
Alopecia 1 0 1.00
Severe sunburn 0 1 0.49
Wolff-Parkinson-White
syndrome
0 1 0.49
Anorexia 0 2 0.24
Cholecystitis or gallstones 2 0 0.50
Elevated bilirubin 1 0 1.00
Ulcerative colitis 0 1 0.49
Diabetes 0 1 0.49
Hypokalaemia 0 1 0.49
Hyperthyroidism 1 0 1.00
Second cancer 2 0 0.50
Tumour recurrence 0 1 0.49
Proteinuria 1 0 1.00
Renal stones 1 0 1.00
Epistaxis 1 0 1.00
Impotence 0 1 0.49
Taste disturbance 1 0 1.00
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A P P E N D I C E S
Appendix 1. Search strategy for Central Register of Controlled Trials (CENTRAL)
Medical interventions:
1. ACE-inhibitor
(ace inhibitor OR ace-inhibitor OR ace inhibitor* OR ace-inhibitor* OR Angiotensin-Converting Enzyme Inhibitors OR Angiotensin
Converting Enzyme Inhibitors OR Angiotensin-Converting Enzyme Antagonists OR Angiotensin Converting Enzyme Antagonists
OR ACE Inhibitors OR Kininase II Inhibitors OR Kininase II Antagonists OR Angiotensin I-Converting Enzyme Inhibitors OR
Angiotensin I Converting Enzyme Inhibitors OR Angiotensin-Converting Enzyme Inhibitor* OR Angiotensin Converting Enzyme
Inhibitor* OR Angiotensin-Converting Enzyme Antagonist* OR Angiotensin Converting Enzyme Antagonist* OR Kininase II In-
hibitor* OR Kininase II Antagonist* OR Angiotensin I-Converting Enzyme Inhibitor* OR Angiotensin I Converting Enzyme In-
hibitor* OR captopril OR enalapril OR fosinopril OR peptidyl dipeptidase OR Peptidyl Dipeptidase A OR Angiotensin I-Converting
Enzyme OR Angiotensin I Converting Enzyme OR Carboxycathepsin OR Kininase A OR CD143 Antigen OR CD143 Antigens OR
Dipeptidyl Peptidase A OR Angiotensin Converting Enzyme OR Kininase II)
2. Angiotensin receptor blocker
(angiotensin receptor blocker OR angiotensin receptor blockers OR angiotensin receptor blocker* OR Angiotensin II Type 1 Receptor
Blockers OR Angiotensin II Type 1 Receptor Antagonists OR Type 1 Angiotensin Receptor Antagonists OR Type 1 Angiotensin
Receptor Blockers OR Selective Angiotensin II Receptor Antagonists OR Sartans OR Angiotensin II OR Angiotensin Receptors/
antagonists & inhibitors OR Angiotensin II Type 1 Receptor Blocker* OR Type 1 Angiotensin Receptor Antagonist* OR Type 1
Angiotensin Receptor Blocker* OR Selective Angiotensin II Receptor Antagonist* OR losartan OR valsartan)
3. Beta-blocker
(beta blockerOR beta blockers OR beta-blockers OR beta-blocker OR beta-blocker* OR beta blocker*ORAdrenergic beta Antagonists
OR adrenergic beta-antagonistsORAdrenergic beta-Receptor BlockadersORAdrenergic beta Receptor BlockadersORbeta-Adrenergic
Receptor Blockaders OR beta Adrenergic Receptor Blockaders OR beta-Adrenergic Blocking Agents OR beta Adrenergic Blocking
Agents OR beta-Adrenergic Blockers OR beta Adrenergic Blockers ORAdrenergic beta-Blockers OR Sympatholytics OR Sympathetic-
Blocking Agents OR Sympathetic Blocking Agents OR Sympatholytic Agents OR Sympatholytic Drugs OR Sympatholytic* OR
Adrenergic beta Antagonist* OR Adrenergic beta-Receptor Blockader* OR Adrenergic beta Receptor Blockader* OR beta-Adrenergic
Receptor Blockader* OR beta Adrenergic Receptor Blockader* OR beta-Adrenergic Blocking Agent* OR beta Adrenergic Blocking
Agent* OR beta Adrenergic Blocker* OR beta-Adrenergic Blocker* OR Adrenergic beta-Blocker* OR Sympathetic-Blocking Agent*
OR Sympathetic Blocking Agent* OR Sympatholytic Agent* OR Sympatholytic Drug* OR carvedilol OR atenolol OR metoprolol
OR propranolol)
4. Calcium channel blocker
(calcium channel blocker OR calcium channel blockers OR calcium channel blocker* OR Exogenous Calcium Antagonists OR
Exogenous Calcium Blockaders OR Calcium Channel Blocking Drugs OR Exogenous Calcium Inhibitors OR Exogenous Calcium
Antagonist* OR Exogenous Calcium Blockader* OR Calcium Channel Blocking Drug* OR Exogenous Calcium Inhibitor* OR
ExogenousCalciumBlockader*ORCalciumChannel BlockingDrug*ORExogenousCalcium Inhibitor*ORdiltiazemORnifedipine)
5. Digoxin
(digoxin OR digoxin* OR Lanoxin)
6. Vasodilator agent
(vasodilator OR vasodilators OR vasodilator* OR vasodilator agents OR Vasodilator Drugs OR Vasoactive Antagonists OR Vasoactive
Antagonist* OR vasodilator agent* OR Vasodilator Drug* OR nitroglycerin OR Glyceryl Trinitrate OR Trinitrate, Glyceryl OR
Nitroglycerin* OR diazoxide OR adenosine)
7. Diuretic
(diuretic OR diuretics OR diuretic* OR furosemide )
8. Aldosterone antagonist
(aldosteron antagonist OR aldosteron antagonists OR aldosterone antagonist OR aldosterone antagonists OR aldosterone antagonist*
OR aldosteron antagonist* OR spironolactone)
9. (Other) antihypertensive agents
(antihypertensiva OR anti-hypertensive OR anti hypertensive OR anti hypertensive drugs OR antihypertensive drugs OR antihy-
pertensive agents OR Anti-Hypertensive Agents OR Anti Hypertensive Agents OR Anti-Hypertensive Drugs OR Anti Hypertensive
Drugs OR Anti-Hypertensives OR Anti Hypertensives OR Antihypertensive Drugs OR Antihypertensives OR antihypertensiv* OR
antihypertensive drug* OR anti hypertensive drug* OR antihypertensive agent* OR anti hypertensive agent* OR clonidine)
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10. Inotropic
(inotropics OR inotropic OR inotropic* OR dopamine OR dobutamine OR epinephrine OR norepinephrine)
11. Growth hormone
(growth hormone OR Pituitary Growth Hormone OR Somatotropin OR Recombinant Pituitary Growth Hormones OR Recombi-
nant Somatotropin OR Recombinant Growth Hormone OR Recombinant Growth Hormones OR Recombinant Somatotropins OR
growth hormon* OR Somatotropin* OR Pituitary Growth Hormon* OR Recombinant Pituitary Growth Hormon* ORRecombinant
Somatotropin* OR Recombinant Growth Hormon*)
Total search strategy for medical interventions:
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11
13. Anthracyclines
anthracyclines OR anthracyclin* OR anthracycline antibiotics OR 4-demethoxydaunorubicin OR 4 demethoxydaunorubicin OR 4-
desmethoxydaunorubicin OR 4 desmethoxydaunorubicin OR IMI 30 OR IMI30 OR IMI-30 OR idarubicin hydrochloride OR
NSC 256439 OR NSC-256439 OR NSC256439 OR idarubicin OR idarubic* OR 4’-epiadriamycin OR 4’ epiadriamycin OR 4’-
epidoxorubicin OR 4’ epidoxorubicin OR 4’-epi-doxorubicin OR 4’ epi doxorubicin OR 4’-epi-adriamycin OR 4’ epi adriamycin OR
4’-epi-DXR OR 4’ epi DXR OR epirubicin hydrochloride OR farmorubicin OR IMI-28 OR IMI 28 OR IMI28 OR NSC 256942
OR NSC-256942 OR NSC256942 OR epirubicin OR epirubic* OR adriablastine OR adriblastin OR adriablastin OR adriamycin
OR DOX-SL OR DOX SL OR doxorubicin hydrochloride OR doxorubic* OR adriamyc* OR dauno-rubidomycine OR dauno
rubidomycin OR rubidomycin OR rubomycin ORdaunomycin OR cerubidine ORdaunoblastin OR daunoblastine ORdaunorubicin
hydrochloride OR hydrochloride, daunorubicin OR daunorubic* OR rubidomyc* OR NSC-82151 OR NSC 82151 OR NSC82151
OR daunoxome OR daunoxom* OR daunosom* OR doxil OR caelyx OR liposomal doxorubicin OR myocet OR doxorubicin OR
daunorubicin
14. Childhood cancer
(leukemia OR leukemi* OR leukaemi* OR (childhood ALL) OR AML OR lymphoma OR lymphom* OR hodgkin* OR T-cell OR
B-cell OR non-hodgkin OR sarcoma OR sarcom* OR Ewing* OR osteosarcoma OR osteosarcom* OR wilms tumor OR wilms* OR
nephroblastom* OR neuroblastoma OR neuroblastom* OR rhabdomyosarcoma OR rhabdomyosarcom* OR teratoma OR teratom*
OR hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET OR medulloblastoma OR medulloblastom* OR
PNET* OR neuroectodermal tumors, primitive OR retinoblastoma OR retinoblastom* ORmeningioma ORmeningiom* OR glioma
OR gliom* OR pediatric oncology OR paediatric oncology OR childhood cancer OR childhood tumor OR childhood tumors OR
cancer or neoplasms or tumor or cancers or neoplasm or tumors)
The final combined search was:
15. 12 AND 13 AND 14
All searches in Title, Abstract or Keywords in Cochrane Central Register of Controlled Trials (CENTRAL).
[*=zero or more characters]
Appendix 2. Search strategy for MEDLINE/PubMed
Medical interventions:
1. ACE-inhibitor
(ace inhibitor OR ace-inhibitor OR ace inhibitor* OR ace-inhibitor* ORAngiotensin-Converting Enzyme Inhibitors ORAngiotensin-
Converting Enzyme Inhibitors[Pharmacological Action] OR Angiotensin Converting Enzyme Inhibitors OR Angiotensin-Converting
Enzyme Antagonists ORAngiotensin Converting Enzyme Antagonists OR Enzyme Antagonists, Angiotensin-Converting OR Antago-
nists, Angiotensin-Converting Enzyme OR Antagonists, Angiotensin Converting Enzyme OR Antagonists, Kininase II OR Inhibitors,
Kininase II OR Inhibitors, ACE OR ACE Inhibitors OR Kininase II Inhibitors OR Kininase II Antagonists OR Angiotensin I-
Converting Enzyme Inhibitors OR Angiotensin I Converting Enzyme Inhibitors OR Inhibitors, Angiotensin-Converting Enzyme OR
Enzyme Inhibitors, Angiotensin-Converting OR Inhibitors, Angiotensin Converting Enzyme OR Angiotensin-Converting Enzyme
Inhibitor* OR Angiotensin Converting Enzyme Inhibitor* OR Angiotensin-Converting Enzyme Antagonist* OR Angiotensin Con-
verting Enzyme Antagonist* OR Kininase II Inhibitor* OR Kininase II Antagonist* ORAngiotensin I-Converting Enzyme Inhibitor*
OR Angiotensin I Converting Enzyme Inhibitor* OR captopril OR enalapril OR fosinopril) OR (peptidyl dipeptidase OR Peptidyl
Dipeptidase A OR Angiotensin I-Converting Enzyme OR Angiotensin I Converting Enzyme OR Carboxycathepsin OR Kininase A
OR CD143 Antigen OR CD143 Antigens OR Dipeptidyl Peptidase A OR Antigens, CD143 OR Angiotensin Converting Enzyme
OR Kininase II)
2. Angiotensin receptor blocker
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(angiotensin receptor blocker OR angiotensin receptor blockers OR angiotensin receptor blocker* OR Angiotensin II Type 1 Receptor
Blockers OR Angiotensin II Type 1 Receptor Antagonists OR Type 1 Angiotensin Receptor Antagonists OR Type 1 Angiotensin
Receptor Blockers OR Selective Angiotensin II Receptor Antagonists OR Sartans OR Angiotensin II OR Angiotensin Receptors/
antagonists & inhibitors OR Angiotensin II Type 1 Receptor Blocker* OR Type 1 Angiotensin Receptor Antagonist* OR Type 1
Angiotensin Receptor Blocker* OR Selective Angiotensin II Receptor Antagonist* OR losartan OR valsartan)
3. Beta-blocker
(beta blockerOR beta blockers OR beta-blockers OR beta-blocker OR beta-blocker* OR beta blocker*ORAdrenergic beta Antagonists
OR adrenergic beta-antagonists OR adrenergic beta-antagonists[Pharmacological Action] OR beta-Antagonists, Adrenergic ORAdren-
ergic beta-Receptor Blockaders OR Adrenergic beta Receptor Blockaders OR Blockaders, Adrenergic beta-Receptor OR beta-Receptor
Blockaders, Adrenergic OR beta-Adrenergic Receptor Blockaders OR Blockaders, beta-Adrenergic Receptor OR Receptor Blockaders,
beta-Adrenergic OR beta Adrenergic Receptor Blockaders OR beta-Adrenergic Blocking Agents OR Agents, beta-Adrenergic Blocking
OR Blocking Agents, beta-Adrenergic OR beta Adrenergic Blocking Agents OR beta-Adrenergic Blockers OR Blockers, beta-Adren-
ergic OR beta Adrenergic Blockers OR beta-Blockers, Adrenergic OR Adrenergic beta-Blockers OR beta Blockers, Adrenergic OR
Sympatholytics OR Sympatholytics[Pharmacological Action] OR Sympathetic-Blocking Agents OR Agents, Sympathetic-Blocking
OR Sympathetic Blocking Agents OR Sympatholytic Agents OR Agents, Sympatholytic OR Sympatholytic Drugs ORDrugs, Sympa-
tholytic OR Sympatholytic* OR Adrenergic beta Antagonist* OR Adrenergic beta-Receptor Blockader* OR Adrenergic beta Receptor
Blockader* OR beta-Adrenergic Receptor Blockader* OR beta Adrenergic Receptor Blockader* OR beta-Adrenergic Blocking Agent*
OR beta Adrenergic Blocking Agent* OR beta Adrenergic Blocker* OR beta-Adrenergic Blocker* OR Adrenergic beta-Blocker* OR
Sympathetic-Blocking Agent* OR Sympathetic Blocking Agent* OR Sympatholytic Agent* OR Sympatholytic Drug* OR carvedilol
OR atenolol OR metoprolol OR propranolol)
4. Calcium channel blocker
(calcium channel blocker OR calcium channel blockers OR calcium channel blockers[Pharmacological Action] OR calcium channel
blocker* OR Exogenous Calcium Antagonists OR Antagonists, Exogenous Calcium OR Calcium Antagonists, Exogenous OR Exoge-
nous Calcium Blockaders OR Blockaders, Exogenous Calcium OR Calcium Inhibitors, Exogenous OR Calcium Channel Blocking
Drugs OR Exogenous Calcium Inhibitors OR Inhibitors, Exogenous Calcium OR Calcium Blockaders, Exogenous OR Channel
Blockers, Calcium OR Blockers, Calcium Channel OR Exogenous Calcium Antagonist* OR Exogenous Calcium Blockader* OR
Calcium Channel Blocking Drug* OR Exogenous Calcium Inhibitor* OR Exogenous Calcium Blockader* OR Calcium Channel
Blocking Drug* OR Exogenous Calcium Inhibitor* OR diltiazem OR nifedipine)
5. Digoxin
(digoxin OR digoxin* OR Lanoxin)
6. Vasodilator agent
(vasodilator OR vasodilators OR vasodilator* OR vasodilator agents OR vasodilator agents[Pharmacological Action] OR Agents,
Vasodilator OR Vasodilator Drugs OR Drugs, Vasodilator OR Vasoactive Antagonists OR Antagonists, Vasoactive OR Vasoactive
Antagonist* OR vasodilator agent* OR Vasodilator Drug* OR nitroglycerin OR Glyceryl Trinitrate OR Trinitrate, Glyceryl OR
Nitroglycerin* OR diazoxide OR adenosine)
7. Diuretic
(diuretic OR diuretics OR diuretic* OR diuretics[Pharmacological Action] OR furosemide )
8. Aldosterone antagonist
(aldosteron antagonist OR aldosteron antagonists OR aldosterone antagonist OR aldosterone antagonists OR aldosterone antagonist*
OR aldosteron antagonist* OR “Aldosterone antagonists”[Pharmacological Action] OR Antagonists, Aldosterone OR spironolactone)
9. (Other) antihypertensive agents
(antihypertensiva OR anti-hypertensive OR anti hypertensive OR anti hypertensive drugs OR antihypertensive drugs OR antihyper-
tensive agents OR antihypertensive agents[Pharmacological Action] OR Agents, Antihypertensive OR Anti-Hypertensive Agents OR
Agents, Anti-Hypertensive OR Anti Hypertensive Agents OR Anti-Hypertensive Drugs OR Anti Hypertensive Drugs OR Drugs,
Anti-Hypertensive OR Anti-Hypertensives OR Anti Hypertensives OR Antihypertensive Drugs OR Drugs, Antihypertensive OR
Antihypertensives OR antihypertensiv* OR antihypertensive drug* OR anti hypertensive drug* OR antihypertensive agent* OR anti
hypertensive agent* OR clonidine)
10. Inotropic
(inotropics OR inotropic OR inotropic* OR dopamine OR dobutamine OR epinephrine OR norepinephrine)
11. Growth hormone
(growth hormone OR Growth Hormone, Pituitary OR Pituitary Growth Hormone OR Somatotropin OR Growth Hormone, Re-
combinant OR Growth Hormones Pituitary, Recombinant OR Pituitary Growth Hormones, Recombinant OR Recombinant Pi-
tuitary Growth Hormones OR Somatotropin, Recombinant OR Recombinant Somatotropin OR Recombinant Growth Hormone
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OR Recombinant Growth Hormones OR Growth Hormones, Recombinant OR Recombinant Somatotropins OR Somatotropins,
Recombinant OR growth hormon* OR Somatotropin* OR Pituitary Growth Hormon* OR Recombinant Pituitary Growth Hormon*
OR Recombinant Somatotropin* OR Recombinant Growth Hormon*)
Total search strategy for medical interventions:
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11
13. Anthracyclines
(anthracyclines OR anthracyclin* OR anthracycline antibiotics OR antibiotics, anthracycline OR 4-demethoxydaunorubicin OR 4
demethoxydaunorubicin OR 4-desmethoxydaunorubicin OR 4 desmethoxydaunorubicin OR IMI 30 OR IMI30 OR IMI-30 OR
idarubicin hydrochloride OR hydrochloride, idarubicin OR NSC 256439 OR NSC-256439 OR NSC256439 OR idarubicin OR
idarubic* OR 4’-epiadriamycin OR 4’ epiadriamycin OR 4’-epidoxorubicin OR 4’ epidoxorubicin OR 4’-epi-doxorubicin OR 4’
epi doxorubicin OR 4’-epi-adriamycin OR 4’ epi adriamycin OR 4’-epi-DXR OR 4’ epi DXR OR epirubicin hydrochloride OR
hydrochloride, epirubicin OR farmorubicin OR IMI-28 OR IMI 28 OR IMI28 ORNSC 256942 ORNSC-256942 ORNSC256942
OR epirubicin OR epirubic* OR adriablastine OR adriblastin OR adriablastin OR adriamycin OR DOX-SL OR DOX SL OR
doxorubicin hydrochloride OR hydrochloride, doxorubicin OR doxorubic* OR adriamyc* OR dauno-rubidomycine OR dauno
rubidomycin OR rubidomycin OR rubomycin ORdaunomycin OR cerubidine ORdaunoblastin OR daunoblastine ORdaunorubicin
hydrochloride OR hydrochloride, daunorubicin OR daunorubic* OR rubidomyc* OR NSC-82151 OR NSC 82151 OR NSC82151
OR daunoxome OR daunoxom* OR daunosom* OR doxil OR caelyx OR liposomal doxorubicin OR doxorubicin, liposomal OR
myocet OR doxorubicin OR daunorubicin)
14. Childhood cancer
(((leukemia OR leukemi* OR leukaemi* OR (childhood ALL) OR AML OR lymphoma OR lymphom* OR hodgkin* OR T-cell OR
B-cell OR non-hodgkin OR sarcoma OR sarcom* OR sarcoma, Ewing’s OR Ewing* OR osteosarcoma OR osteosarcom* OR wilms
tumor OR wilms* OR nephroblastom* OR neuroblastoma OR neuroblastom* OR rhabdomyosarcoma OR rhabdomyosarcom* OR
teratoma OR teratom* OR hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET OR medulloblastoma OR
medulloblastom* OR PNET* OR neuroectodermal tumors, primitive OR retinoblastoma OR retinoblastom* OR meningioma OR
meningiom* OR glioma OR gliom*) OR (pediatric oncology OR paediatric oncology)) OR (childhood cancer OR childhood tumor
OR childhood tumors)) OR (cancer or neoplasms or tumor or cancers or neoplasm or tumors)
15. RCTs, CCTs
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR
randomly[tiab] OR trial[tiab] OR groups[tiab]) AND humans[mh]
The final combined search was:
16. 12 AND 13 AND 14 AND 15
[pt = publication type; tiab = title, abstract; sh = subject heading; mh = MeSH term; *=zero or more characters; RCT = randomized
controlled trial; CCT = controlled clinical trial]
Appendix 3. Search strategy for EMBASE/OVID
1. Medical interventions
1. (ace inhibitor or ace-inhibitor or ace inhibitor$ or ace-inhibitor$).mp.
2. Dipeptidyl Carboxypeptidase Inhibitor/ or (angiotensin converting enzyme inhibitor or angiotensin converting enzyme inhibitors
or angiotensin converting enzyme inhibitor$).mp.
3. (angiotensin-converting enzyme inhibitor or angiotensin-converting enzyme inhibitors or angiotensin-converting enzyme in-
hibitor$).mp.
4. (angiotensin-converting enzyme antagonist or angiotensin-converting enzyme antagonists or angiotensin-converting enzyme antag-
onist$ or angiotensin converting enzyme antagonist or angiotensin converting enzyme antagonists or angiotensin converting enzyme
antagonist$).mp.
5. (kininase II inhibitor or kininase II inhibitors or kininase II inhibitor$ or kininase II antagonist or kininase antagonists or kininase
antagonist$).mp.
6. (angiotensin I-converting enzyme inhibitors or angiotensin I converting enzyme inhibitors or angiotensin I-converting enzyme
inhibitor$ or angiotensin I converting enzyme inhibitor$).mp.
7. (peptidyl dipeptidase or peptidyl dipeptidase A).mp. or exp Dipeptidyl Carboxypeptidase/
8. exp Kininase/ or Kininase A.mp.
9. (Angiotensin I-Converting Enzyme or Angiotensin I Converting Enzyme).mp.
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10. exp Dipeptidyl Peptidase/ or Dipeptidyl Peptidase A.mp.
11. (Carboxycathepsin or Angiotensin Converting Enzyme or Kininase II).mp.
12. (CD143 Antigen or CD143 Antigens).mp.
13. (captopril or enalapril or fosinopril).mp. or exp Captopril Plus Hydrochlorothiazide/ or exp Captopril/ or exp Enalapril Maleate/
or exp Enalapril Plus Hydrochlorothiazide/ or exp Enalapril/ or exp Enalapril Maleate Plus Nitrendipine/ or exp Enalapril Maleate
Plus Felodipine/ or exp Diltiazem Plus Enalapril Maleate/ or exp Fosinopril/ [mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manufacturer name]
14. (angiotensin receptor blocker or angiotensin receptor blockers or angiotensin receptor blocker$).mp.
15. (angiotensin II type 1 receptor blockers or angiotensin II type 2 receptor blocker$).mp. or exp Angiotensin Receptor Antagonist/
16. (angiotensin II type 1 receptor antagonists or type 1 angiotensin receptor antagonists or type 1 angiotensin receptor blocker$ or
type 1 angiotensin receptor blockers or type 1 angiotensin receptor antagonist$).mp.
17. exp Angiotensin Antagonist/ or exp Angiotensin/ or exp Angiotensin 2 Receptor Antagonist/ or exp Angiotensin II Antagonist/
18. (selective angiotensin II receptor antagonists or selective angiotensin II receptor antogonist$ or sartans or angiotensin II).mp.
19. (losartan or valsartan).mp. or exp Losartan/ or exp Hydrochlorothiazide Plus Losartan/ or exp Losartan Potassium/ or exp Hy-
drochlorothiazide Plus Valsartan/ or exp Amlodipine Plus Valsartan/ or exp Valsartan/
20. (beta blocker or beta blockers or beta blocker$ or beta-blocker or beta-blockers or beta-blocker$).mp.
21. exp Beta Adrenergic Receptor Blocking Agent/
22. (adrenergic beta-antagonists or adrenergic beta antagonists).mp.
23. (adrenergic beta-receptor blockaders or adrenergic beta receptor blockaders or beta-adrenergic receptor blockaders or beta adrenergic
receptor blockaders).mp.
24. (beta-adrenergic blocking agents or beta adregenic blocking agents or beta-adrenergic blockers or beta adrenergic blockers or
adrenergic beta-blockers or adrenergic beta blockers).mp.
25. (sympatholytics or sympathetic-blocking agents or sympathetic blocking agents or sympatholytic agents or sympatholytic drugs or
sympatholytic$).mp.
26. (adrenergic beta antagonist$ or adrenergic beta-receptor blockader$ or adrenergic beta receptor blockader$ or beta-adrenergic
receptor blockader$ or beta adrenergic receptor blockader$ or beta-adrenergic blocking agent$ or beta adrenergic blocking agent$).mp.
27. (beta adrenergic blocker$ or beta-adrenergic blocker$ or adrenergic beta-blocker$ or sympathetic-blocking agent$ or sympathetic
blocking agent$ or sympatholytic agent$ or sympatholytic drug$).mp.
28. (carvedilol or atenolol or metoprolol or propanolol).mp. or exp carvedilol/ or exp atenolol plus chlortalidone/ or exp atenolol/ or
exp atenolol plus nifedipine/ or exp metoprolol tartrate/ or exp metoprolol/ or exp metoprolol fumarate/ or exp metoprolol succinate/
or exp propranolol/
29. (calcium channel blocker or calcium channel blockers or calcium channel blocker$).mp.
30. exp Calcium Channel Blocking Agent/
31. exp Calcium Antagonist/ or (exogenous calcium antagonists or exogenous calcium blockaders or calcium channel blocking
drugs).mp.
32. (exogenous calcium inhibitors or exogenous calcium antagonist$ or exogenous calcium blockader$ or calcium channel blocking
drug$).mp.
33. (exogenous calcium inhibitor$ or exogenous calcium blockader$ or calcium channel blocking drug$ or exogenous calcium in-
hibitor$).mp.
34. exp Diltiazem Derivative/ or exp Diltiazem/ or exp Diltiazem Plus Enalapril Maleate/ or exp Nefedipine/ or (diltiazem or nefedip-
ine).mp.
35. exp DIGOXIN/
36. (digoxin or digoxin$ or lanoxin).mp.
37. (vasodilator or vasodilators or vasodilator$).mp.
38. exp Vasodilator Agent/ or (vasodilator agents or vasodilator agent$ or vasodilator drugs or vasodilator drug$ or vasoactive antagonists
or vasoactive antagonist$).mp.
39. (nitroglycerin or glyceryl trinitrate or nitroglycerin$ or diazoxide or adenosine).mp.
40. exp diazoxide/ or exp glyceryl trinitrate/
41. (diuretic or diuretics or diuretic$).mp.
42. exp Diuretic Agent/ or exp Furosemide Plus Triamterene/ or exp Furosemide/ or furosemide.mp.
43. (aldosteron antagonist or aldosteron antagonists or aldosterone antagonist aldosterone antagonists or aldosterone antagonist$).mp.
44. exp Aldosterone Antagonist/ or spironolacton.mp. or exp Spironolactone/
45. (antihypertensiva or antihypertensive or anti hypertensive or anti-hypertensive).mp.
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46. exp Antihypertensive Agent/
47. (anti hypertensive drugs or anti-hypertensive drugs or antihypertensive drugs or antihypertensive agents or anti-hypertensive agents
or anti hypertensive agents).mp.
48. (anti-hypertensives or anti hypertensives or antihypertensives).mp.
49. (antihypertensiv$ or antihypertensive drug$ or anti hypertensive drug$ or antihypertensive agent$ or anti hypertensive agent$).mp.
50. exp Clonidine Derivative/ or clonidine.mp. or exp Clonidine/ or exp Clonidine Displacing Substance/
51. (inotropic or inotropics or inotropic$).mp.
52. exp dopamine/ or exp dobutamine/ or exp adrenalin/ or exp noradrenaline/ or (dopamine or dobutamine or epinephrine or
norepinephrine).mp.
53. (growth hormone or pituitary growth hormone).mp. or exp Growth Hormone/
54. (somatropin or recombinant somatotropin).mp. or exp recombinant growth hormone/ or recombinant pituitary growth hor-
mones.mp.
55. (recombinant growth hormone or recombinant growth hormones or recombinant somatotropins).mp.
56. (growth hormon$ or somatotropin$ or pituitary growth hormon$ or recombinant pituitary growth hormon$ or recombinant
somatotropin$ or recombinant growth hormon$).mp.
57. or/1-56
2. Anthracyclines
1. (anthracyclin$ or anthracyclines).mp. or exp Anthracycline/
2. anthracycline antibiotics.mp. or exp Anthracycline Antibiotic Agent/
3. exp Anthracycline Derivative/
4. (4-demethoxydaunorubicin or 4 demethoxydaunorubicin or 4-desmethoxydaunorubicin or 4 desmethoxydaunorubicin).mp. or exp
idarubicin/
5. (IMI 30 or IMI30 OR IMI-30 or idarubicin hydrochloride).mp.
6. (NSC 256439 or NSC-256439 or NSC256349 or idarubicin or idarubic$).mp.
7. (4’-epiadriamycin or 4’ epiadriamycin or 4’-epidoxorubicin or 4’ epidoxorubicin or 4’-epi-doxorubicin or 4’ epi doxorubicin).mp.
8. (4’-epi-adriamycin or 4’ epi adriamycin or 4’-epi-DXR or 4’ epi DXR).mp.
9. exp epirubicin/ or (epirubicin or epirubicin hydrochloride or epirubic$ or farmorubicin).mp.
10. (IMI-28 or IMI 28 or IMI28 or NSC 256942 or NSC-256942 or NSC256942).mp.
11. (adriablastine or adriblastin or adriablastin or adriamycin).mp.
12. (DOX-SL or DOX SL or doxorubicin hydrochloride or doxorubic$ or adramyc$).mp.
13. (dauno-rubidomycine or dauno rubidomycin or rubidomycin or rubomycin or daunomycin).mp.
14. (cerubidine or daunoblastin or daunoblastine or daunorubicin hydrochloride or daunorubic$).mp.
15. (NSC-82151 or NSC 82151 or NSC82151).mp.
16. (daunoxome or daunoxom$ or daunosom$ or doxil or caelyx or liposomal doxorubicin or myocet or doxorubicin or daunoru-
bicin).mp.
17. expDAUNORUBICINDERIVATIVE/ or expDAUNORUBICIN/ or exp IDARUBICINDERIVATIVE/ or exp IDARUBICIN/
or exp DOXORUBICIN DERIVATIVE/ or exp DOXORUBICIN/ or exp EPIRUBICIN/
18. or/1-17
3. Childhood cancer
1. (leukemia or leukemi$ or leukaemi$ or (childhood adj ALL) or acute lymphocytic leukemia).mp.
2. (AML or lymphoma or lymphom$ or hodgkin or hodgkin$ or T-cell or B-cell or non-hodgkin).mp.
3. (sarcoma or sarcom$ or Ewing$ or osteosarcoma or osteosarcom$ or wilms tumor or wilms$).mp.
4. (nephroblastom$ or neuroblastoma or neuroblastom$ or rhabdomyosarcoma or rhabdomyosarcom$ or teratoma or teratom$ or
hepatoma or hepatom$ or hepatoblastoma or hepatoblastom$).mp.
5. (PNET or medulloblastoma or medulloblastom$ or PNET$ or neuroectodermal tumors or primitive neuroectodermal tumor$ or
retinoblastoma or retinoblastom$ or meningioma or meningiom$ or glioma or gliom$).mp.
6. (pediatric oncology or paediatric oncology).mp.
7. ((childhood adj cancer) or (childhood adj tumor) or (childhood adj tumors) or childhoodmalignancy or (childhood adj malignancies)
or childhood neoplasm$).mp.
8. ((pediatric adj malignancy) or (pediatric adj malignancies) or (paediatric adj malignancy) or (paediatric adj malignancies)).mp.
9. ((brain adj tumor$) or (brain adj tumour$) or (brain adj neoplasms) or (brain adj cancer$) or brain neoplasm$).mp.
10. (central nervous system tumor$ or central nervous system neoplasm or central nervous system neoplasms or central nervous system
tumour$).mp.
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11. intracranial neoplasm$.mp.
12. LEUKEMIA/ or LYMPHOMA/ or brain tumor/ or central nervous system tumor/ or teratoma/ or sarcoma/ or osteosarcoma/
13. nephroblastoma/ or neuroblastoma/ or rhabdomyosarcoma/ or hepatoblastoma/ or medulloblastoma/ or neuroectodermal tumor/
or retinoblastoma/ or meningioma/ or glioma/ or childhood cancer/
14. or/1-13
4. RCTs, CCTs
1. Randomized Controlled Trial/
2. Controlled Clinical Trial/
3. randomized.ti,ab.
4. placebo.ti,ab.
5. randomly.ti,ab.
6. trial.ti,ab.
7. groups.ti,ab.
8. drug therapy.sh.
9. or/1-8
10. Human/
11. 9 and 10
The final combined search was:
5. 1 AND 2 AND 3 AND 4
[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name;
sh = subject heading; ti,ab = title, abstract; / = Emtree term; $=zero or more characters ; RCT = randomized controlled trial; CCT =
controlled clinical trial]
Appendix 4. Search strategy for trial registers
(anthracycline or daunorubicin or doxorubicin or adriamycin or idarubicin or epirubicin or farmorubicin or daunoxome or liposomal
doxorubicin) and (heart failure or heart toxicity or cardiac toxicity or cardiotoxicity)
Appendix 5. Search strategy for conference proceedings
(anthracycline or daunorubicin or doxorubicin or adriamycin or idarubicin or epirubicin or farmorubicin or daunoxome or liposomal
doxorubicin) and (heart failure or heart toxicity or cardiac toxicity or cardiotoxicity) and (child or pediatric) and trial
WH A T ’ S N E W
Last assessed as up-to-date: 25 September 2015.
Date Event Description
1 October 2015 New citation required but conclusions have not
changed
Unfortunately, we could include no new studies in the
review. As a result the conclusions have not changed
25 September 2015 New search has been performed The search for eligible studies was updated to 25
September 2015
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C O N T R I B U T I O N S O F A U T H O R S
Daniel Cheuk performed the updated search, contributed to the interpretation of the results, and wrote and revised the manuscript.
Elske Sieswerda performed the updated search, contributed to the interpretation of the results, and critically reviewed the updated
review.
Elvira van Dalen contributed to the interpretation of the results and reviewed the updated review.
Aleida Postma contributed to the interpretation of the results and critically reviewed the updated review.
Leontien Kremer contributed to the interpretation of the results and critically reviewed the updated review.
D E C L A R A T I O N S O F I N T E R E S T
Daniel Cheuk: None known.
Elske Sieswerda: None known.
Elvira van Dalen: None known.
Aleida Postma: None known.
Leontien Kremer: None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Stichting Kinderen Kankervrij (KiKa), Netherlands.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As opposed to the protocol, which stated that we would use the criteria and definitions in the module of Cochrane Childhood Cancer
(as available in 2008: Module CCG), we based the ’Risk of bias’ assessment on both the earlier mentioned module and on information
provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). We added new items (that is generation of
allocation sequence, selective outcome reporting, and other sources of bias) and adjusted some definitions.
Based on a peer reviewer’s comment, we added to the methods section the Fisher’s exact test, P for situations in which only one study
was available and there were no events in one of the treatment groups.
One review author performed the data extraction and ’Risk of bias’ assessment of included studies, which another review author checked.
We did not contact authors in order to obtain missing data during the data extraction and ’Risk of bias’ assessment.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adult Survivors of Child Adverse Events; Angiotensin-Converting Enzyme Inhibitors [adverse effects; ∗therapeutic use]; Anthracyclines
[∗administration & dosage; adverse effects]; Antibiotics, Antineoplastic [∗adverse effects]; Cardiotonic Agents [∗therapeutic use];
Enalapril [adverse effects; ∗therapeutic use]; Heart Failure [chemically induced; ∗drug therapy; mortality]; Neoplasms [drug therapy];
Phosphocreatine [∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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